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Abstract: The 27th annual GP2A (Groupement des Pharmacochimistes de l′Arc Atlantique/Group of
Medicinal Chemists in the Atlantic Arc) conference took place from 21 to 23 August 2019, at the East
Midlands Conference Centre (University Park, Nottingham, United Kingdom) and was hosted by the
Division of Biomolecular Science and Medicinal Chemistry (BSMC), within the School of Pharmacy at
the University of Nottingham. The event brought together an international delegation of researchers
with interests in medicinal chemistry and interfacing disciplines. In addition, a pre-conference
workshop provided an opportunity for younger researchers to develop their theoretical knowledge
in quantitative pharmacology. Abstracts of presentations by the 14 invited speakers and 6 young
researchers, in addition to 41 posters, are included in this report.
Keywords: medicinal chemistry; drug design; chemical biology; ligand kinetics
1. Aim and Scope of the Meeting
The GP2A (Groupement des Pharmacochimistes de l′Arc Atlantique/Group of Medicinal Chemists
in the Atlantic Arc) network is made up of researchers in the field of medicinal chemistry working in
universities and research institutes across Europe. It was founded in 1992 with the aim of bringing
together researchers to exchange ideas and expertise and facilitate a friendly collaborative networking
environment. Historically, it has included members from France, Spain, Portugal, Ireland and the
United Kingdom (the “Atlantic Arc”). More recently, it has expanded both geographically and in terms
of research fields, now including researchers from areas that range from physical and pharmaceutical
chemistry to molecular pharmacology.
The annual GP2A conference host city alternates between France and another country and brings
together established scientists and those earlier in their career. In addition, the network facilitates
short visits between laboratories. A consistent theme of the annual conference is to provide young
researchers an opportunity to present their work to an international audience through either poster
presentation or by sharing the stage with invited speakers.
The 2019 conference was held at the East Midlands Conference Centre and hosted by the Division
of Biomolecular Science and Medicinal Chemistry (BSMC), within the School of Pharmacy at the
University of Nottingham (UoN). Ahead of the workshop, young researchers were invited to attend
a pre-conference workshop, led by Prof. Steven J. Charlton (UoN/Excellerate Bioscience) and Dr
Elizabeth Rosethorne (UoN). The meeting opened and closed with two internationally recognised
plenary speakers, Prof. Peter Gmeiner (Friedrich-Alexander University, Erlangen-Nürnberg, Germany)
and Prof. Rob Leurs (Vrije-Universiteit, Amsterdam, The Netherlands). In addition, there were
a further 12 invited speaker talks, 6 young researcher talks and 41 posters, selected from over
50 submitted abstracts.
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Reflective of the multidisciplinary nature of medicinal chemistry research, the meeting
included a broad range of topics of interest. These included infectious and neurodegenerative
diseases, chemoprevention of cancer, approaches to target identification, hit identification and
optimisation for drug candidates, natural products, inflammatory diseases/pain and the application of
structural cheminformatics.
2. Pre-Conference Workshop on Quantitative Pharmacology
Comparing the pharmacological characteristics of compounds across different systems
(e.g., different assays and/or cell types) can be a complex task. More difficult still is the extrapolation of
these in vitro data to in vivo systems through PK/PD modelling. In order to make these tasks as accurate
as possible, it is critical to define quantitative, system independent measures of compound action.
This workshop will introduce the concept of quantitative molecular pharmacology and detail the
experimental and analytical methods used to determine key system-independent pharmacological
descriptors of both drug binding and functional efficacy. It will culminate in a team-based exercise
where you will put the knowledge and skills gained from the morning′s lectures into practice. You
will play the role of the pharmacologist in a (fictitious) pharmaceutical company′s due diligence team,
tasked with identifying the best compound to in-license for a respiratory indication. These deals can be
very expensive—will you be confident enough in your analysis to make a recommendation to senior
management . . . ?
3. Opening Plenary Lecture
Selective Ligands Based on GPCR Structures
Peter Gmeiner
Department of Chemistry and Pharmacy, Medicinal Chemistry, Emil Fischer Center, Friedrich-Alexander
University, Nikolaus-Fiebiger- Str. 10, 91058 Erlangen, Germany; peter.gmeiner@fau.de
GPCR crystal structures may leverage an effective development of novel drug candidates because
they can be used for structure-based in silico docking screens, giving access to new chemotypes
and, as a consequence, to new biological profiles (Shoichet, B.K., Kobilka, B.K. Trends Pharmacol. Sci.
2012, 33, 268–272). Furthermore, they can guide lead modification and optimization programs by
providing insights into crucial ligand–receptor interactions and the bioactive ligand conformation.
Both strategies can be performed on the basis of either the crystal structure of a given GPCR or from a
homology model of a structurally highly similar congener. Structures of different activity states of
GPCRs allow us to identify molecular interactions discriminating between inverse agonists, antagonists
and agonists. These fundamental results also contribute to the rational discovery of drugs selectively
binding to particular conformational states.
We aim to leverage GPCR structures to discover new chemotypes and bioisosteres with beneficial
physical and biological properties and use these to probe and control signalling pathways. Thus, we
develop highly specific agonists and antagonists for Class A GPCRs for structural and functional
investigations and for structure–function relationship studies. The final goal is the development of
novel drug candidates.
The seminar will show very recent developments in the design, synthesis and biological
investigation of orthosteric and allosteric GPCR ligands with unprecedented activity profiles.
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Structure-guided development of highly specific GPCR ligands. 
4. Closing Plenary Lecture 
It is All About Time….. 
Rob Leurs 
Department of Medicinal Chemistry, Vrije Universiteit Amsterdam, 1081 HZ Amsterdam, The 
Netherlands; e-mail: r.leurs@vu.nl 
In light of the recent interest in drug binding kinetics, we have investigated the kinetics of the 
binding interactions between the classical antihistamines and the H1R within the framework of the 
Innovative Medicines Initiative-sponsored program “Kinetics for Drug Discovery (K4DD)”. We 
developed new methodologies to measure and study GPCR-ligand kinetics and investigated the 
relationship between the drug structure and the drug-receptor binding kinetics (i.e., structure kinetics 
relationship, SKR). A better understanding of this relationship should provide a handle for the 
rational drug optimization of the kinetic binding profile of antihistamines. 
Large differences in H1R binding kinetics were observed between different antihistamines that 
were not always reflected by the strength of the binding interaction (affinity). It was additionally 
shown that differences in the binding kinetics of antihistamines at the H1R affect their mode of 
antagonism of the GPCR, independent of their binding affinity. For ligands binding the H1R, several 
sub-structures were linked to an increase in the receptor residence time. Moreover, several of the 
newer generation antihistamines (e.g., levocetirizine, olopatadine, rupatadine) contained one or 
multiple of these chemical structures, explaining their long residence time at the H1R and most likely 
also their therapeutic success. 
This, together with evidence presented in the scientific literature, suggests that kinetic analyses 
of drug-receptor binding have added value for the development of new drugs. Focus on a better 
understanding of the molecular interactions that are formed between the drug and receptor over time 
and the relationship with ligand binding rate constants are therefore a step forward in the 
development of effective GPCR ligands. 
5. Keynote Lectures 
5.1. The Design and Development of Keap1-Nrf2 Interaction Inhibitors and Their Biological Activity (KL1) 
Nikolaous Georgakopoulos, Jemma Gatliff and Geoff Wells 
UCL School of Pharmacy, University College London, London WC1N 1AX, United Kingdom; e-mail: 
g.wells@ucl.ac.uk 
The therapeutic potential of Nrf2-inducing molecules spans several disease states including 
chronic neurodegenerative diseases, inflammatory conditions and possible roles in cancer 
4. Closing Plenary Lecture
It is ll bout Ti e . . . ..
ob Leurs
epart ent of Medicinal Chemistry, Vrije Universiteit Amsterdam, 1081 HZ Amsterdam,
The Netherlands; r.leurs@vu.nl
In light of the recent interest in drug binding kinetics, we have investigated the kinetics of
the binding interactions between the classical antihistamines and the H1R within the framework
of the Innovative Medicines Initiative-sponsored program “Kinetics for Drug Discovery (K4DD)”.
We developed new methodologies to measure and study GPCR-ligand kinetics and investigated the
relationship bet een the drug structure and the drug-receptor binding kinetics (i.e., structure kinetics
relationship, SKR). A better understanding of this relationship should provide a handle for the rational
drug optimization of the kinetic binding profile of antihistamines.
Large differences in 1R binding kinetics ere observed bet een different antihista ines that
ere not al ays reflected by the strength of the binding interaction (affinity). It as additionally
sho n that differences in the binding kinetics of antihista ines at the 1R affect their ode of
antagonis of the P R, independent of their binding affinity. For ligands binding the 1R, several
sub-structures were linked to an increase in the receptor residence time. Moreover, several of the newer
generation antihistamines (e.g., levocetirizine, olopatadine, rupatadine) contained one or multiple of
these chemical structures, explaining their long residence time at the H1R and most likely also their
therapeutic success.
This, together ith evidence presented in the scientific literature, suggests that kinetic analyses
of drug-receptor binding have added value for the develop ent of ne drugs. Focus on a better
understanding of the olecular interactions that are for ed bet een the drug and receptor over ti e
and the relationship with ligand binding rate constants are therefore a step forward in the development
of effective GPCR ligands.
5.1. The esign and evelop ent of eap1- rf2 Interaction Inhibitors and Their Biological ctivity ( L1)
ikolaous Georgakopoulos, Jem a Gatliff and Geoff Wells
L School of Phar acy, niversity ollege London, London 1 1 , K; g.wells@ucl.ac.uk
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The therapeutic potential of Nrf2-inducing molecules spans several disease states including chronic
neurodegenerative diseases, inflammatory conditions and possible roles in cancer chemoprevention.
Conversely, targeted use of Nrf2 inhibitors may have applications in cancer treatment regimens
(Cuadrado, A., et al. Nat. Rev. Drug Disc. 2019, 18, 295–317).
Our research has been directed towards identifying both reversible and irreversible inhibitors of
the Keap1-Nrf2 protein–protein interaction. Reactive inducers have been developed from a previous
class of multi-targeted redox homeostasis modulators. On the other hand, reversible inhibitors of
Keap1 are the product of structure-based design utilising peptide and small molecule leads. We
have identified high affinity sulphonamide ligands for Keap1 (IC50 < 1 nM) and compounds with
non-standard binding modes utilising X-ray crystallography studies.
In our analysis of the biological activity of these compounds, we characterised effects on
mitochondrial function and quality control processes, and autophagy that differ between reversible
and irreversible Nrf2 inducers. Differences in mitochondrial turnover, ROS and biogenesis appear to
distinguish the two types of Nrf2 inducer across several distinct chemotypes.
The activity of these small molecules can contribute to understanding the biological activities of
different classes of Nrf2 inducers, their therapeutic utility and potential off-target effects and toxicity.
5.2. Novel Antikinetoplastid Nitroaromatics Bioactivated by Type 1 NTRs (KL2)
P. Verhaeghe
Faculté des Sciences Pharmaceutiques, Université Paul Sabatier and Laboratoire de Chimie
de Coordination, UPR CNRS 8241, 205 route de Narbonne, 31077 Toulouse cedex, France;
pierre.verhaeghe@univ-tlse3.fr
Kinetoplastids are a group of flagellated parasites including Leishmania ssp. and Trypanosoma ssp.
that are responsible for several neglected tropical diseases (NTD): visceral leishmaniasis (VL), human
African trypanosomiasis (HAT) and Chagas disease (CD), globally responsible for about 30,000 annual
deaths, according to the WHO. There are few drugs on the market against these parasitic diseases
that affect people living in developing countries. Moreover, most of these drugs present severe
side effects and are not orally available. In this worrying context, a new drug called Fexinidazole,
a 5-nitroimidazole derivative developed by Sanofi and DNDi, was approved in 2018 by the EMA
against HAT and is being evaluated in phase II against CD. Nevertheless, there is still no new chemical
entity that clinically studied against VL. Working on nitroaromatic derivatives displaying anti-infective
potential, our group identified two novel antileishmanial pharmacophores in 8-nitroquinolin-(1H)-one
and 3-nitroimidazo [1, 2-a] pyridine series (Paloque, L., et al. Eur. J. Med. Chem. 2012, 54, 75–86;
Castera-Ducros, C., et al. Bioorg. Med. Chem. 2013, 21, 7155–7164; Kieffer, C., et al. Eur. J. Med. Chem.
2015, 92, 282–294; Kieffer, C., et al. Bioorg. Med. Chem. 2015, 23, 2377–2386).
By synthesizing more than 200 derivatives, electrochemistry-guided pharmacomodulation studies
progressively led to several potent and selective in vitro hit-compounds presenting IC50 values ranging
10 from 10 µM to nM against L. donovani (pro. & ama.), L. infantum (axe. ama.), T. b. brucei (trypo.) and
T cruzi (epi.), low cytotoxicities on the human HepG2 cell line and high selectivity indices (from 10 to
400). We then demonstrated that, like for fexinidazole, these nitroaromatic molecules are selectively
bioactivated by type 1 nitroreductases, probably leading to cytotoxic electrophilic reduction metabolites
such as nitroso and hydroxylamine derivatives. In both series, hit-compounds were not genotoxic
in the comet assay and even the mutagenicity Ames test was negative for several imidazopyridine
derivatives. The determination of some preliminary in vitro pharmacokinetic parameters highlighted
good microsomal stability (T1/2 > 40 min), high albumin binding (98%–99%) and blood–brain barrier
diffusion (BBB PAMPA) in quinolinone series, whereas some metabolic issues needed additional work
in imidazopyridine series to reach optimized hit-molecules that are now able to undergo in vivo
evaluations on mouse models (Pedron, J., et al. Eur. J. Med. Chem. 2018, 155, 135–152; Pedron, J., et al.
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5.3. Small Molecule Drugs and Where to Find Them—Approaches to Hit Finding, New and Old (KL3) 
Prof. Michael J. Waring 
Chemistry, School of Natural and Environmental Sciences, Newcastle University, Bedson Building, 
Newcastle upon Tyne NE1 7RU, United Kingdom; e-mail: mike.waring@ncl.ac.uk 
The technologies available to the medicinal chemist for finding hit molecules for proteins of 
interest have expanded rapidly in recent years. From extensive use of high-throughput screening to 
now well-established fragment-based methods to emerging technologies (Murray, C.W., Rees, D.C. 
Nature Chem. 2009, 1, 187–192) such as DNA-encoded chemical libraries (Favalli, N., et al. FEBS Lett. 
2018, 592, 2168–2180), the range of complementary techniques is enabling more rapid drug-discovery, 
including approaches to more challenging targets. The central premises to all these approaches 
remain—how to select protein targets that are amenable to small molecule modulation in a manner 
compatible with ADMET properties and how to design screening libraries that generate the best 
quality hits for optimisation. 
The talk will describe past optimisation programmes demonstrating where the hits came from 
and why these enabled the progression of the project. It will then outline how some of the identified 
concepts might be applied to future hit finding and some new approaches we are developing, such 
as Fraglite screening, which uses minimal halogenated fragments that express hydrogen bonding 
doublet motifs to assess druggability and inform future hit finding (Wood, D.J., et al. J. Med. Chem. 
2019, 62, 3741–3752). 
5.4. Development of Small Molecule Glial Cell Line-Derived Neurotrophic Factor (GDNF) Family Ligand 
Mimetics for the Treatment of Neurodegenerative Diseases and Pain (KL4) 
Yulia A. Sidorova, Arun Mahato and Mart Saarma 
Institute of Biotechnology, HiLIFE, University of Helsinki, FIN-00014 Helsinki, Finland; e-mail: 
yulia.sidorova@helsinki.fi 
Neurotrophic factors are secretory proteins that by binding to their cognate receptors trigger 
intracellular signalling promoting neuron survival, neurite outgrowth and regulate neuronal 
plasticity. Glial cell line-derived neurotrophic factor (GDNF) family consist of four factors GDNF, 
neurturin (NRTN), artemin (ARTN) and persephin (PSPN) that first bind to the GPI-anchored GDNF 
receptor family alpha (GFRa) and then activate the transmembrane tyrosine kinase RET. GDNF 
family ligands (GFLs) have neurotrophic effects on sensory, dopamine, sympathetic, 
parasympathetic, enteric neurons and motoneurons. A recently discovered novel member of the GFL 
family, a protein called GDF15, signals via the GFRAL-RET pathway and regulates body weight in 
many diseases (Saarma, M., Goldman, A. Nature 2017, 550, 195–197). GDNF and NRTN have been 
tested in phase II clinical trials on Parkinson′s disease patients showing modest effects that are in 
principle promising although statistically insignificant. ARTN has been tested in phase I clinical trials 
for neuropathic pain. To understand the molecular mechanisms of ligand receptor interactions, we 
solved the GDNF-GFRa1 complex structure at 2.35 Å resolution, identified amino acid residues 
involved in this interaction and residues possibly interacting with RET (Parkash, V., et al. J. Biol. 
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Mimetics for the Treatment of Neurodegenerative Diseases and Pain (KL4)
Yulia A. Sidorova, Arun Mahato and Mart Saarma
InstituteofBiotechnology, HiLIFE,UniversityofHelsinki, FIN-00014Helsinki, Finland; yulia.sidorova@helsinki.fi
Neurotrophic factors are secretory proteins that by binding to their cognate receptors trigger
intracellular signalling promoting neuron survival, neurite outgrowth and regulate neuronal plasticity.
Glial cell line-derived neurotrophic factor (GDNF) family consist of four factors GDNF, neurturin
(NRTN), artemin (ARTN) and persephin (PSPN) that first bind to the GPI-anchored GDNF receptor
family alpha (GFRa) and then activate the transmembrane tyrosine kinase RET. GDNF family ligands
(GFLs) have neurotrophic effects on sensory, dopamine, sympathetic, parasympathetic, enteric neurons
and motoneurons. A recently discovered novel member of the GFL family, a protein called GDF15,
signals via the GFRAL-RET pathway and regulates body weight in many diseases (Saarma, M.,
Goldman, A. Nature 2017, 550, 195–197). GDNF and NRTN have been tested in phase II clinical trials on
Parkinson′s disease patients showing modest effects that are in principle promising although statistically
insignificant. ARTN has been tested in phase I clinical trials for neuropathic pain. To understand the
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molecular mechanisms of ligand receptor interactions, we solved the GDNF-GFRa1 complex structure
at 2.35 Å resolution, identified amino acid residues involved in this interaction and residues possibly
interacting with RET (Parkash, V., et al. J. Biol. Chem. 2008, 283, 35164–35172). Results of structural
studies together with the notion that GFL proteins have poor pharmacological properties, encouraging
us to develop small molecules that act similarly to GFLs. The major drawback hindering clinical use of
GFLs is inability of these proteins to cross tissue barriers and limited tissue distribution, which restricts
their clinical efficacy. We developed medium- and high-throughput methods to identify agonists
of GFL receptors and screened a chemical library of 18,000 drug-like compounds. We identified a
molecule named BT13 that activated GFL receptor RET and its down-stream signalling cascades in
immortalized cells, as well as in sensory and dopamine neurons. In cultured dorsal root ganglion
neurons BT13 activated Akt, Erk and Src intracellular signalling cascades and, in the ARTN-like
fashion, stimulated elongation and arborisation of neurites of peptidergic neurons (Sidorova, Y.A., et al.
Front. Pharmacol. 2017, 8, 365). In rodent spinal nerve ligation (SNL)-induced neuropathic pain model
BT13, with equal efficacy with ARTN protein, the surgery-induced mechanical hypersensitivity and
normalized the expression of multiple neuronal markers were decreased. BT13 penetrated through the
blood–brain barrier, supported the survival of cultured dopamine neurons at 100 nM, alleviated motor
symptoms of PD in a rat 6-OHDA model and showed a trend to increase the density of DA fibres in
striatum. Using medicinal chemistry and different screening methods, we developed next generation
GFL mimetics with improved efficacy, solubility and stability of the compounds. They are currently
being tested in animal models of neuropathic pain and Parkinson′s disease. Novel GFL mimetics can
be hopefully used also for therapeutic intervention in obesity and in palliative cancer care, as RET
activation by GDF15 regulates body weight.
5.5. The Holy Grail of Opioid Analgesia? (KL5)
Gerta Cami-Kobeci 1, Mei-Chuan Ko 2, John R Traynor 3 and S M Husbands 1
1 Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK
2 Department of Physiology and Pharmacology, Wake Forest School of Medicine, Winston-Salem,
NC, USA
3 Department of Pharmacology, University of Michigan, Ann Arbor, USA; s.m.husbands@bath.ac.uk
The opioid epidemic has rapidly evolved into a medical crisis, with recent figures suggesting
11.5 million people in the United States had misused prescription opioids and >17,000 deaths had been
caused by commonly prescribed opioids in 2016 alone. A long sought-after but elusive solution has been
the development of a strong but safe opioid analgesic—The Holy Grail of opioid research. Our approach
has been to develop analgesics, such as BU08028 (Ding, H., et al. PNAS, 2016, 113, E5511–E5518),
with partial agonist activity at both mu and nociceptin/orphanin FQ peptide receptors, as evidence
suggests a synergistic interaction between these receptors for analgesia. BU08028 proved to be a potent,
long-acting analgesic in primates and did not cause respiratory dependence or reduce respiration.
Having defined a pharmacophore for mixed mu and nociception receptor binding, we were able to
design a further series of mixed ligands based on the oxymorphone scaffold. BU10038 was identified
from within this series as having an almost identical receptor profile to BU08028 and has now been
evaluated in a battery of assays to define its analgesic and side effect profile (Kiguchi, N., et al. Brit. J.
Anaesthesia, 2019, 122, e146–e156). Following systemic administration in non-human primates, BU10038
(0.001–0.01 mg kg−1) dose-dependently produced long-lasting antinociceptive and antihypersensitive
effects. Unlike the standard analgesic oxycodone, BU10038 lacked reinforcing effects (i.e., had little or
no abuse liability), and compromised the physiological functions of primates including respiration,
cardiovascular activities and body temperature at antinociceptive doses and at a 10–30-fold higher dose
(0.01–0.1 mg kg−1). Unlike morphine, BU10038 did not cause the development of physical dependence
and tolerance after repeated and chronic administration. This work strongly supports the development
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Funding from the National Institute on Drug Abuse and Orexigen Therapeutics. 
5.6. Design of Matrix Metalloproteinase Inhibitors for Inflammatory Bowel Disease (KL6) 
Maria Pigott, Jun Wang, Shane O′Sullivan, Carlos Medina and John F Gilmer 
School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, D2, Ireland; e-mail: 
gilmerjf@tcd.ie 
Matrix metalloproteinases (MMPs) is an umbrella term for a large family of widely distributed 
enzymes that influence diverse biochemical processes relevant to normal physiology and to disease. 
MMPs are interesting drug targets but they are challenging because of their distribution, range of 
effects and similarity. The so-called gelatinase B enzyme, also known as MMP-9, is a key player in 
the progression of inflammatory bowel disease (IBD) and a marker of inflammation and disease 
progression (O′Sullivan, S., et al. Mediat. Inflamm. 2015, 2015, 1–18). This talk will describe the biology 
of MMP-9 in IBD and provide an overview of our attempts to design inhibitors that selectively affect 
its function. These efforts relate to three broad strategies: (i) attempts at increasing MMP-9 selectivity 
in the pyrimidinetrione class through conventional medicinal chemistry approaches (Wang, J., et al. 
Bioorg. Med. Chem. 2011, 19, 16, 4985–4999); (ii) hybrid tactics using nitric oxide mimetic functionality 
to influence MMP transcription (O′Sullivan, S., et al. Br. J. Pharmacol. 2017, 174, 512–524; Wang. J.; 
O′Sullivan, S., et al. J. Med. Chem. 2012, 55, 2154–2162); (iii) quasi pharmaceutical strategies to confine 
broadly unselective pyrimidinetrione inhibitors to disease tissue through manipulation of chemical 
properties. The outcomes of these attempts and lessons learned will be related through data from in 
vitro/in vivo models of ulcerative colitis. 
5.7. Computational Medicinal Chemistry Approaches for GPCR Structure-Based Drug Discovery (KL7) 
Chris De Graaf 
Sosei Heptares; e-mail: Chris.DeGraaf@heptares.com 
Novel crystal structures of GPCR-ligand complexes solved at Sosei Heptares and elsewhere 
continue to reveal a diversity of potential ligand binding sites. Emerging sets of GPCR crystal 
structures of multiple diverse ligands bound to closely related receptors furthermore finally enable a 
protein structure-based view of how different ligands bind this major drug target class. 
This presentation will address several important repercussions and learnings from the analysis 
of GPCR structures for ligand design that should be transferable and relevant for many targets, both 
GPCRs and enzymes, including: 
• Caveats in using pharmacophore-based similarity principles for modeling receptor ligand 
complexes different ligand chemotypes. 
• The important roles of lipophilic hot spots and water networks as drivers of GPCR druggability, 
ligand binding and selectivity. 
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5.6. Design of Matrix Metalloproteinase Inhibitors for Inflammatory Bowel Disease (KL6)
Maria Pigott, Jun Wang, Shane O′Sullivan, Carlos Medina and John F Gilmer
School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, D2, Ireland; gilmerjf@tcd.ie
Matrix metalloproteinases (MMPs) is an umbrella term for a large family of widely distributed
enzymes that influence diverse biochemical processes relevant to normal physiology and to disease.
MMPs are interesting drug targets but they are challenging because of their distribution, range of
effects and similarity. The so-called gelatinase B enzyme, also known as MMP-9, is a key player
in the progression of inflammatory bowel disease (IBD) and a marker of inflammation and disease
progression (O′Sullivan, S., et al. Mediat. Inflamm. 2015, 2015, 1–18). This talk will describe the biology
of MMP-9 in IBD and provide an overview of our attempts to design inhibitors that selectively affect
its function. These efforts relate to three broad strategies: (i) attempts at increasing MMP-9 selectivity
in the pyrimidinetrione class through conventional medicinal chemistry approaches (Wang, J., et al.
Bioorg. Med. Chem. 2011, 19, 16, 4985–4999); (ii) hybrid tactics using nitric oxide mimetic functionality
to influence MMP transcription (O′Sullivan, S., et al. Br. J. Pharmacol. 2017, 174, 512–524; Wang. J.;
O′Sullivan, S., et al. J. Med. Chem. 2012, 55, 2154–2162); (iii) quasi pharmaceutical strategies to confine
broadly unselective pyrimidinetrione inhibitors to disease tissue through manipulation of chemical
properties. The outcomes of these attempts and lessons learned will be related through data from
in vitro/in vivo models of ulcerative colitis.
5.7. Computational Medicinal Chemistry Approaches for GPCR Structure-Based Drug Discovery (KL7)
Chris De Graaf
Sosei Heptares; Chris.DeGraaf@heptares.com
Novel crystal structures of GPCR-ligand complexes solved at Sosei Heptares and elsewhere
continue to reveal a diversity of potential ligand binding sites. Emerging sets of GPCR crystal
structures of multiple diverse ligands bound to closely related receptors furthermore finally enable a
protein structure-based view of how different ligands bind this major drug target class.
This presentation will address several important repercussions and learnings from the analysis
of GPCR structures for ligand design that should be transferable and relevant for many targets,
both GPCRs and enzymes, including:
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• Caveats in using pharmacophore-based similarity principles for modeling receptor ligand
complexes different ligand chemotypes.
• The important roles of lipophilic hot spots and water networks as drivers of GPCR druggability,
ligand binding and selectivity.
• Binding mode diversity of (chemically similar) ligands across the structural GPCRome.
This presentation will show how the breakthroughs in GPCR structural biology can be
complemented by computational and experimental studies for a more accurate description and
prediction of molecular and structural determinants of ligand-receptor binding affinity, kinetics,
potency and selectivity. Integrated cheminformatics workflows will be described that combine
structural, pharmacological and chemical data to explore receptor–ligand interaction space and steer
structure-based virtual ligand screening. Novel cheminformatics-driven molecule design approaches
will be discussed, combining retrosynthetic analysis, library enumeration approaches (e.g., matched
molecular pairs analysis) and recurrent neural network-driven molecule generation.
We will discuss how the accumulated GPCR structural chemogenomics data can be used to
construct customized structure-based medicinal chemistry toolboxes for hit optimization and library
design. Orthogonal physics-based (Molecular Dynamics, e.g., Free Energy Perturbation FEP+,
WaterMap from Schrödinger) and empirical (e.g., GRID and WaterFLAP from Molecular Discovery)
structure-based drug design methods will be presented to target lipophilic hotspots, water networks
and cryptic ligand binding pockets for a variety of GPCR subfamilies.
5.8. Phenotypic Activity Driven Target Identification and Discovery of Drug Candidates (KL8)
Paul Wyatt
Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, University of Dundee, School of
Life Sciences, Dundee DD1 5EH, UK; P.G.Wyatt@dundee.ac.uk
There are considerable opportunities for drug discovery centres based in universities to generate
benefit to patients, provided they do not compete with or merely replicate BioPharma. The centres have
to develop activities complementary to, or in partnership with the BioPharma industry. These include
partially de-risking novel drug discovery targets, or tackling neglected and orphan diseases. The Drug
Discovery Unit seeks to achieve this by combining a globally rare university-based, fully integrated
drug discovery group capable of delivering new drug candidates with a world-class life sciences
research environment and multiple partners to develop the drug discovery approaches to major
global diseases.
The talk describes how we are delivering much needed clinical candidates, for example, malaria
and visceral leishmaniasis (two) by taking a phenotypic approach to hit identification and optimisation,
using mode of action studies to identify novel drug targets and to manage a portfolio of phenotypically
derived projects.
5.9. Resin Acid-Driven Innovations in Antimicrobial Research (KL9)
Vânia M. Moreira 1,2
1 Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, United
Kingdom, 161 Cathedral Street, G4 0RE Glasgow; vania.moreira@strath.ac.uk
2 Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy,
University of Helsinki, Finland, Viikinkaari 5 E, P.O. Box 56, FI-00014 University of Helsinki
Humans have employed resins for esthetic, ceremonial or therapeutic uses for millennia
(Klemens, F., Dieter, G. “Resins, Natural”. Ullmann′s Encyclopedia of Industrial Chemistry, 2000).
Gum rosin, in particular, has an annual worldwide production of more than 1 million tons and is used
as an ingredient for inks, varnishes, adhesives, cosmetics, medicines and chewing gums. The ecological
role of resins is protective, that is, when trees are cut, the volatiles in the resin evaporate leaving
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the solid portion that contains “resin acids”, which shelter them from external stress and invaders,
promoting healing.
Our research has revealed that these “resin acids”, belonging to the class of abietane-type
diterpenoids, have antimicrobial and anti-biofilm activity towards gram-positive bacteria and can be
exploited for human use (Fallarero, A., et al. Int. J. Mol. Sci. 2013, 14, 12054–12072). Through chemistry,
we have created a library of over 50 new chemically pure “resin acids” derivatives, which includes,
to the best of our knowledge, the most potent agents reported within their class so far (Manner, S., et al.
Eur. J. Med. Chem. 2015, 102, 68–79; Moreira, V.M., et al. WO 2016/051013 A1, 7th April 2016). It is
noteworthy that this effect is accompanied by a good tolerability profile and low potential for spreading
resistance. Moreover, combination of these compounds with nanocellulose, an advanced biopolymer
with excellent mechanical properties and biocompatibility, resulted in innovative and cost-effective
functional surfaces, bearing a broad spectrum of action against bacteria, high biocompatibility and
no cross-resistance with drug-resistant strains (Hassan, G., et al. ACS Sustainable Chem. Eng. 2019, 7,
5002–5009). This presentation will detail the outcomes of our work with this class of compounds and
further illustrate how natural products and their derivatives foster innovation in antimicrobial research.
Acknowledgements: The Finnish Funding Agency for Technology and Innovation (project
1297/31/2016).
5.10. Glycoconjugates Disrupting Bacterial and Fungal Adhesion Mechanisms (KL10)
Sébastien G. Gouin
University of Nantes, CEISAM, Chimie Et Interdisciplinarité, Synthèse, Analyse, Modélisation, UMR
CNRS 6230, UFR des Sciences et des Techniques, 2, rue de la Houssinière, BP 92208, 44322 NANTES
Cedex 3, France; sebastien.gouin@univ-nantes.fr
Increasing resistance to antibiotics or antifungals is a serious health problem, which is worsening
with the constant identification of strains resilient to commonly available chemotherapeutic agents.
Among the therapeutic alternatives developed at the academic level, the anti-adhesive strategy has seen
a growing interest in the last 25 years (Cecioni, S., et al. Chem. Rev. 2015, 115, 525–561). The concept is
to disrupt the lectin-mediated adhesion of the pathogen to eukaryotic cells. This therapeutic approach
should be less prone to the development of resistances and selection pressures, as the pathogens are
not killed during the decolonisation process.
Our group is interested in developping antagonists of carbohydrate-binding and processing
proteins (adhesins and glycosidases) to disrupt the attachment of pathogenic bacteria and fungi to
host cells. We will discuss the design of mono- and multivalent glycoconjugates and their in vitro
and in vivo antiadhesif potential. A specific focus will be made on antagonists of adhesins (Figure 1)
(Brument, S., et al. J. Med. Chem. 2013, 56, 5395–5406; Brissonnet, Y., et al. J. Am. Chem. Soc.
2013, 135, 18427–18435; Brissonnet, Y., et al. Chem. Eur. J. 2019, 25, 2358–2365; Alvarez Dorta, D., et al.
ChemBioChem 2016, 17, 936–952) or invasive aspergillosis (Lehot, V., et al. Chem. Eur. J. 2018, 24,
19243–19249).
5.11. Drug-Like Properties and Ligand Efficiency-Guided Optimisation (KL11)
Paul Leeson
Paul Leeson Consulting Ltd. and School of Pharmacy, University of Nottingham, UK; leesonpd@gmail.com
It has been acknowledged that significant attrition and delay in clinical drug development
pipelines has been caused by poor compound properties such as inadequate pharmacokinetics and
poor solubility. Generic compound quality guidelines, such as the rule of five, may not always be
helpful because differing drug binding sites on biological targets can strongly influence the allowable
physicochemical property ranges of their ligands. The application of ligand efficiency measures, which
quantify in vitro activities per unit of a physical property such as size or lipophilicity, provides an
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improved perspective of compound quality over physicochemical properties alone. Thus, candidate
drugs and approved drugs are frequently amongst the most ligand efficient for their specific target,
on the basis of measures using both size (ligand efficiency, LE) and lipophilicity (ligand lipophilic
efficiency, LLE). This is seen even with drugs having extreme physicochemical properties, such as
those breaking the rule of five, for example, the new raft of drugs for treatment of the hepatitis C
virus. The desirable optimisation destination in the property efficiency space of a novel target can be
anticipated once enough screening data are available, usually in the hit-to-lead phase. In conjunction
with the application of multiparameter ADMET optimisation, the approach can help to refine drug
design options, prioritise synthesis and reduce the numbers of compounds made (Young, R.J., et al.
J. Med. Chem. 2018, 61, 6421–6467).
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5.12. Natural Products and Analogues as Potential Therapeutic Agents (KL12)
Diego Cortes 1, María Jesús Sanz 1,2 and Nuria Cabedo 2
1 Department of Pharmacology, University of Valencia, Burjassot, Spain, 46100
2 Biomedical Research Institute INCLIVA, 46010 Valencia, Spain; ncabedo@uv.es
Natural products have been the most valuable inspiration for the synthesis of novel therapeutic
agents. Among them, heterocyclic moieties are prevalent in pharmacologically relevant drugs
(Cortes, D. Bioactive Secondary Metabolites: The Drugs that Nature provides. 2018. Cortes D. (Ed).
ISBN-10: 171877768X; ISBN-13: 978–1718777682. CreateSpace). In the course of our research on
synthesis of bioactive heterocycles, we synthetized novel isoquinolines as dopaminergic ligands,
including tetrahydroisoquinolines carbamates (Parravicini, O., et al. J. Mol. Model. 2017, 23, 273),
hexahydrocyclopenta-IQ (HCPIQ)(Figure 2) (Parraga, J., et al. Eur. J. Med. Chem. 2016, 122, 27–42),
aporphines (Moreno, L., et al. Bioorg. Med. Chem. Lett. 2013, 23, 4824–4827), phenanthrenes
(Moreno, L, et al. Bioorg. Med. Chem. Lett. 2013, 23, 4824–4827) and protoberberines (Párraga, J., et al.
Eur. J. Med. Chem. 2013, 68, 150–166). Dopaminergic ligands can bind to subfamily D1-like (D1, D5) and
D2-like (D2-D4) dopamine receptors (DR) to “restore” the dopaminergic pathway. From a therapeutic
point of view, DR are the main target for antipsychotic (neuroleptics) and antiparkinsonian drugs.
Recently, we demonstrated by binding experiments and functional assays that some of these compounds
displayed affinity for DR with high selectivity for D2-like DR, behaving as dopaminergic agonists.
Molecular modelling studies have established the main molecular interactions that stabilize the different
ligand-receptor complexes (Parravicini, O., et al. J. Mol. Model. 2017, 23, 273; Parraga, J., et al. Eur. J.
Med. Chem. 2016, 122, 27–42).
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Figure 2. Molecular graph of the molecular interactions between hexahydrocyclopenta-IQ (HCPIQ) 3e
and hydrophobic residues: Val115, Ile183, Ile184, Trp386, Phe389, Phe390, His393, Thr412 and Tyr416 of
D2 dopamine receptors (DR).
In recent years, considerable attention has been paid on melatonergic (MT) receptor
agonists given their application for treating insomnia and depression. We synthetized novel
hexahydroindenopyridines (HHIP), which were able to bind MT1 and/or MT2 receptors. These HHIP
emerged as promising leads for the development of new melatoninergic agents (Parraga, J., et al. Eur. J.
Med. Chem. 2014, 30, 700–709).
This work was funded by grants SAF2017–89714-R, SAF2014–57845R, CP15/00150 and PI18/01450
from Ministerio de Ciencia, Innovación, Instituto de Salud Carlos III and co-funded by European
Union (ERDF/ ESF) “Investing in your future”.
6. Young Researcher Communications
6.1. Pyrroloquinolones as Novel Dual-Targeting and Dual-Stage Oral Efficacious Antimalarials (YRC01)
Gustavo da Silva 1,2, Lis Coelho 3, Diana Fontinha 4, Vera L. M. Silva 2, Artur M. S. Silva 2 and
Rui Moreira 1
1 iMed.ULisboa, Faculdade de Farmácia da Universidade de Lisboa, Lisboa, Portugal, 1649–003
2 Department QOPNA, Departamento de Química da Universidade de Aveiro, 3810–193 Aveiro, Portugal
3 Centro da Malária e Doenças Tropicais, IHMT, Universidade Nova de Lisboa, 1349–008 Lisboa, Portugal
4 Instituto de Medicina Molecular, Faculdade de Medicina Universidade de Lisboa, 1649–028 Lisboa,
Portugal; galfdsilva@ff.ulisboa.pt
In this communication, we report the results from a medicinal chemistry programme focused
on a pyrroloquinolone (PQ) series targeting the Plasmodium falciparum mETC (mitochondrial
electron transport chain). This previously unknown series 1 was tested against blood- and
liver-stage malaria parasites and our hit compound revealed excellent dual-stage inhibitory activity.
The plausible structure–activity relationships and the inhibition of mETC components (cytochrome
bc1, dihydroorotate dehydrogenase) will be discussed in this communication. In addition, our hit
compound interfered with calcium homeostasis in transgenic malaria parasites. The interactions
between the lead compounds and target were confirmed by docking. Our hit compound also revealed
a good selectivity index, in vivo efficacy and favourable pharmacokinetic properties (Figure 3).
This work was supported by Fundação para a Ciência e Tecnologia (FCT), FEDER and PT2020
through projects UID/DTP/04138/2013 and UID/QUI/00062/2013. We also thank FCT for the fellowships
SFRH/BPD/108807/2015 (V.L.M.S.) and SFRH/BD/103412/2014 (G.S.).
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Prostaglandins and leukotriens (LTs), produced from arachidonic acid by cyclo-oxygenase and 
5-lipoxygenase (5-LOX) pathways, respectively, are key mediators in inflammation (Funk, C. D. 
Science 2001, 294, 1871–1875). Our recent results showed an anti-inflammatory activity of ω-oxidized 
tocotrienols by inhibiting 5-LOX (Pein, H., et al. Nat. Commun. 2018, 9, 3834). Amongst these 
compounds, δ-garcinoic acid (δ-GA) was the most active one. It inhibited LTs formation in 5-LOX 
and polymorphonuclear leukocyte assays with IC50 at 0.04 ± 0.02 µM and 0.35 ± 0.08 µM, respectively. 
Molecular docking with an in-house dataset was performed and identified new allosteric binding site 
for these compounds. 
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Prostaglandins and leukotriens (LTs), produced from arachidonic acid by cyclo-oxygenase and
5-lipoxygenase (5-LOX) pathways, respectively, are key mediators in inflammation (Funk, C. D.
Science 2001, 294, 1871–1875). Our recent results showed an anti-inflammatory activity ofω-oxidized
tocotrienols by inhibiting 5-LOX (Pein, H., et al. Nat. Commun. 2018, 9, 3834). Amongst these
compounds, δ-garcinoic acid (δ-GA) was the most active one. It inhibited LTs formation in 5-LOX and
polymorphonuclear leukocyte assays with IC50 at 0.04 ± 0.02 µM and 0.35 ± 0.08 µM, respectively.
Molecular docking with an in-house dataset was performed and identified new allosteric binding site
for these compounds.
In order to further understand the mode of action and to improve the 5-LOX inhibitory activity
of δ-GA or its pharmacological profile, the rational design of a series of amides followed by their
semisynthesis was carried out. Here, we present a dataset of novel δ-GA-based anti-inflammatory
agents with promising in vitro and in cellulo anti-inflammatory activity.
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1, Sylvie Claeysen 3, Maria-Laura Bolognesi 2, Patrick Dallemagne 1 and Christophe Rochais 1 
1 Normandie Univ, UNICAEN, CERMN, 14000 Caen, France.  
2 Department of Pharmaceutical Sciences, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy.  
3 IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France; e-mail: caroline.lanthier@gmail.com 
In a world where life expectancy is increasing, Alzheimer disease (AD) is the main cause of 
dementia, and affects approximatively 17% of people who are older than 75 years in France. This is a 
progressive neurodegenerative disorder characterized by memory loss and cognitive decline. Despite 
the fact that the physiopathology of AD is not entirely known at the current time, some molecular 
causes were found such as the ß-amyloid peptides aggregation, tau-dependent neurofibrillary 
tangles, as well as oxidative stress and neuroinflammation. Currently, treatments available for 
patients are mainly acetylcholine esterase (AChE) inhibitors, which only have symptomatic benefits 
and do not cure AD. Thus, there is still a strong medical need in the AD population. 
In this context, the concept of multi-target directed ligands (MTDLs) was applied to design a 
drug with several therapeutic targets. The envisaged MTDL (targeted structure—Figure 4) should be 
able to limit the development of ß-amyloid plaques obtained by the aggregation of ß-amyloid 
peptides (Aß). Indeed, our compounds are designed to promote the cleavage of amyloid protein 
precursor (APP) by α -secretase activation in order to produce a neuroprotective and soluble peptide 
sAPPα. This is the role of the 5HT4R agonists, which are already studied in the CERMN (Centre 
d'Etudes et de Recherche sur le Médicament de Normandie) in other MTDL projects and led to the 
discovery of donecopride (blue part—Figure 1) (Rochais, C., et al. J. Med. Chem., 2015, 58, 3172–3187). 
On the other hand, it appears that oxidative stress plays a central role in AD (Rosini, M., et al. J. Med. 
Chem., 2014, 57, 2821–2831). Adding antioxidant moiety such as polyphenol, lipoic and ferulic acid 
(red part—Figure 1) could trap free radicals or reactive oxygen species (ROS) and also have a 
neuroprotective effect. This aspect has been widely studied in Prof. Maria-Laura Bolognesi′s 
laboratory over the years (Bolognesi, M.-L., et al. J. Med. Chem., 2009, 52, 7883–7886). To that end, 
different compounds will be designed and synthesized, with both the expertise of CERMN and Prof. 
Maria-Laura Bolognesi, in order to evaluate their in vitro/in vivo properties regarding their agonist 
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In a world where life expectancy is increasing, Alzhei er disease (AD) is the main cause of
dementia, and affects approximatively 17% of people who are older than 75 years in France. This is a
progressive n ur degenerative disorder character zed by memory loss and cognitive decli e. Despite
the fact that the physiopathology of AD is no entirely known at the current ime, some molecular
causes were found such as the ß-amyloid peptides aggregation, tau-dependent neurofibrillary tangles,
as well as oxidative stress and neuroinflammation. Currently, treatments available for patients are
mainly acetylcholine esterase (AChE) inhibitors, which only have symptomatic benefits and do not
cure AD. Thus, there is still a strong medical need in the AD population.
In this context, the concept of multi-target directed ligands (MTDLs) was applied to design a drug
with several therapeutic targets. The envisaged MTDL (targeted structure—Figure 4) should be able
to limit the development of ß-amyloid plaques obtained by the aggregation of ß-amyloid peptides
(Aß). Indeed, our compounds are designed to promote the cleavage of amyloid protein precursor
(APP) by α -secretase activation in order to produce a neuroprotective and soluble peptide sAPPα.
This is the role of the 5HT4R agonists, which are already studied in the CERMN (Centre d’Etudes
et de Recherche sur le Médicament de Normandie) in other MTDL projects and led to the discovery
of donecopride (blue part—Figure 1) (Rochais, C., et al. J. Med. Chem., 2015, 58, 3172–3187). On the
other hand, it appears that oxidative stress plays a central role in AD (Rosini, M., et al. J. Med. Chem.,
2014, 57, 2821–2831). Adding antioxidant moiety such as polyphenol, lipoic and ferulic acid (red
part—Figure 1) could trap free radicals or reactive oxygen species (ROS) and also have a neuroprotective
effect. This aspect has been widely studied in Prof. Maria-Laura Bolognesi′s laboratory over the years
(Bolognesi, M.-L., et al. J. Med. Chem., 2009, 52, 7883–7886). To that end, different compounds will
be designed and synthesized, with both the expertise of CERMN and Prof. Maria-Laura Bolognesi,
in order to evaluate their in vitro/in vivo properties regarding their agonist activity on 5-HT4R and
antioxidant properties. The development and promising in vitro/in cellulo results of the chloroaniline′s
moiety line will be described in this presentation.
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Figure 4. Targeted structure, with 5-HT4R agonist moiety in blue and antioxidant moieties in red.
6.4. Reactivity of Pazopanib and Sunitinib Aldehyde Metabolites toward Proteins: Potential Involvement in
Hepatotoxicity and Drug–Drug Interactions (YRC04)
Marie-Noëlle Paludetto 1, Jean-Luc Stigliani 2, Anne Robert 2, Vania Bernardes-Génisson 2,
Etienne Chatelut 1, Florent Puisset 1 and Cécile Arellano 1
1 Centre de Recherches en Cancérologie de Toulouse (CRCT), University of Toulouse, 31037 Toulouse, France
2 Laboratoire de Chimie de Coordination du CNRS (LCC-CNRS), University of Toulouse, 31077 Toulouse,
France; paludetto.marienoelle@iuct-oncopole.fr
Pazopanib and sunitinib are tyrosine kinase inhibitors (TKI) approved for the treatment of various
cancers. Their hepatotoxicity has been highlighted by the black boxed warnings issued by the FDA in
their drug labels. These TKI are mainly metabolized by hepatic cytochromes P450 (CYP), and previous
in vitro studies have suggested that they are CYP3A4 time-dependant inhibitors (Kenny, J. R., et al.
Pharm. Res. 2012, 29, 1960–1976; Filppula, A. M., et al. Drug Metab. Dispos. 2014, 42, 1202–1209).
New reactive metabolites (RM) with aldehyde structures have been discovered during pazopanib
and sunitinib metabolism (Paludetto, M-N., et al. J. Med. Chem. 2018, 61, 7849–7860). Aldehydes are
hard electrophiles that have a high reactivity potential toward proteins and that are thought to be
responsible for CYP inactivation, drug–drug interactions (DDI) and hepatotoxicity (Kalgutkar, A. S.
Chem. Res. Toxicol. 2017, 30, 220–238).
The reactivity of pazopanib and sunitinib aldehyde RM toward different hepatic (human liver
microsomes (HLM), recombinant CYP3A4) and plasma (albumin) proteins was investigated by
LC-MS/MS to better understand how these RM could be involved in liver toxicity and DDI. Because
of the presence of a free amino group on its side chain, lysine could be a good target for reactive
electrophiles. Reactions between aldehydes and amines affording imine derivatives are known to
be reversible in aqueous media. Thus, adduct formation with these different proteins was examined
after reductive amination of imine derivatives by NaBH3CN in vitro and after proteolytic digestion.
Preliminary studies were carried out with free lysine and aldehyde RM generated beforehand
by biomimetic oxidation reactions catalysed by metalloporphyrins. Lysine adduct formation was
then studied with aldehyde RM generated in situ in HLM and recombinant CYP3A4 incubations.
Aldehyde-lysine adducts on both CYP3A4 and plasma proteins were detected for the first time
by LC-MS for pazopanib and sunitinib and characterized by the related [M+H]+ ions and MS/MS
fragmentation patterns. In addition, the formation of aldehyde RM in vivo was investigated in plasma
samples from patients treated, separately, with pazopanib or sunitinib. These aldehyde RM have
been unambiguously detected in patient plasma samples during drug monitoring. Thus, it could be
hypothesized that the coupling of pazopanib or sunitinib aldehydes with lysine residues of CYP3A4
and hepatic proteins may be involved both in hepatotoxicity and DDI.
6.5. Click Chemistry Tools to Unravel New Targets in Malaria (YRC05)
Jorge Grilo 1,2, Lara Fidalgo 1, Diana Fontinha 2, Beatriz Anacleto 1, Charlie Saunders 3, Edward W. Tate 3,
Rui Moreira 1, Miguel Prudêncio 2 and Ana S. Ressurreição 1
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1 Research Institute for Medicines—iMed. ULisboa, Faculdade de Farmácia da Universidade de Lisboa,
1649–003 Lisbon, Portugal
2 iMM—Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, 1649–028
Lisbon, Portugal
3 Department of Chemistry, Imperial College London White City Campus, London W12 0BZ, UK;
jhfgrilo@ff.ulisboa.pt
Despite the best efforts and investment from the last decade, malaria′s death toll still amounts to
nearly half a million people a year, and no reduction of the diagnosed cases was observed in the last
two years. Furthermore, parasite resistance is already reported for every drug class in clinical use.
These makes this protozoan infection a major public health concern mainly in the tropical regions of
the globe (WHO. World Malaria Report. 2018). To overcome these hurdles, it is critical to advance new
drugs with different mechanisms of action.
With that in mind, we have already disclosed Torin2, known as an ATP-competitive mTOR kinase
inhibitor (Liu, Q., et al. J. Med. Chem. 2011, 54, 1473), as a portent antimalarial lead compound that
possesses in vivo activity in mice against the blood and liver stages. Compound activity was shown to
be independent of the host mTOR pathway and does not involve the mechanisms already knows for
drugs in clinic (Hanson, K. K., et al. Proc. Natl. Acad. Sci. U.S.A. 2013, 110, E2838).
Here, we report the development of Torin2 photoaffinity-based probes to deconvolute the
molecular target(s) of this compound in the parasite. This was achieved through the modification of
the core scaffold with a photocrosslinker and a handle suitable for ‘click chemistry’. Furthermore, we
disclose the application of these chemical tools in a mass spectrometry-based proteome profiling of
P. falciparum lysates and live cultures of the disease blood stage (Scheme 1). The results thus obtained
are fundamental optimization of Torin2-based compounds as a new alternative to current antimalarials,
a key breakthrough to address the existing therapeutic gap.
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Scheme 1. (A) Torin2 hit compound; (B) structure of the photo-affinity labelling probe I, derived
from Torin2 by the introduction of a diazirine photoreactive moiety (in red) and a terminal alkyne
handle for CuAAC chemistry (in green) and (C) schematic overview of the methodology applied for
Plasmodium falciparum cell-based proteome profiling. In red: Diazirine before (star) and after (circle)
irradiation. In pink: TAMRA and/or Biotin azide capture reagents.
Acknowledgements: FCT-Portugal, (PTDC/QEQ-MED/7097/2014)(PD/BD/128260/2016)
(IF/01034/2014).
6.6. The Development of a 6-Chloro-3-(Thiazole)Methyl-Quinazolin-4(3H)-One Series as Inhibitors of PqsR,
the Transcripti nal Regul tor of the Pqs Quorum S nsing System Pseudomonas aeruginosa. (YRC06)
Scott Grossman 1, Fadi Soukarieh 2, Paul Williams 2, Miguel Cámara 2 and Michael J. Stocks 1
1 School of Pharmacy, Nottingham NG7 2RD, UK
2 School f Life Sciences, Natio al Biofilms Innovation Centre, Centre for Biomolecular Sciences, University
of Nottingham, Nottingham, Nottinghamshire NG7 2RD, UK; scott.grossman@nottingham.ac.uk
As the rise in antimicrobial resistance continues to reduce treatment options for a variety of
pathogens at an alarming rate, the need for alternate antimicrobial agents grows ever more urgent.
Pharmaceuticals 2019, 12, 179 16 of 47
One such approach gaining ever more interest is the attenuation of virulence through the silencing
of quorum sensing, a form of community-based cell-to-cell communication. The opportunistic
pathogen Pseudomonas aeruginosa is the greatest contributor to morbidity in cystic fibrosis patients,
and causes chronic and persistent infections in immunocompromised patients, particularly in a
hospital environment.
Previous studies have evidenced the attenuation of virulence through the suppression of its
alkylquinolone-based quorum sensing system, Pseudomonas quinolone system (pqs) (Ilangovan, A., et al.
PLoS Pathog. 2013, 9, e1003508). Herein, we report the synthesis and biological evaluation of a
novel series of 6-chloro-3-(thiazole)methyl-quinazolin-4(3H)-one compounds (Figure 1) through the
determination of their biological activity using both P. aeruginosa PAO1-L mCTX:PpqsA-lux and PA14
mCTX:PpqsA-lux bioreporter strains. We report structural evaluation of their binding mode through
generating protein–ligand crystal structures of this class of novel inhibitors in the PqsR ligand binding
domain. The structure–activity relationship (SAR) study verified the binding mode to be comparable
with that of the natural agonists HHQ and PQS, whilst providing lead pqs inhibitors with IC50s in the
100 nM range.
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7.1. Design and Synthesis of New Integrated Stress Response Inhibitor (ISRIB) Analogues Targeting eIF2B 
as Potential Candidates for Enhancing Protein Synthesis Rate (P01) 
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Neurodegenerative diseases represent the major cause of dementia, which is predominantly a 
disease of the elderly, and is characterised by a decline in cognitive functions and memory. All these 
diseases share a similar aetiology, that is, the production and accumulation of misfolded proteins in 
the brain. This results in increasing the activity of the protein kinase RNA-like endoplasmic reticulum 
kinase PERK/eIF2α-P pathway of the unfolded protein response (UPR), which in turn leads to the 
inhibition of protein synthesis. According to a recent study the small-molecule integrated stress 
response inhibitor (ISRIB) reduces the level of eIF2α-P by activating eukaryotic initiation factor 2B 
(eIF2B), a guanine nucleotide exchange factor (GEF) for eIF2α, resulting in enhancement of protein 
synthesis based on in vivo study in the cell-based luciferase reporter assay (Sidrauski, C., et al. Elife. 
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Neurodegenerative diseases represent the major cause of dementia, which is predominantly a
disease of the elderly, and is characterised by a decline in cognitive functions and memory. All these
diseases share a similar aetiology, that is, the production and accumulation of misfolded proteins in
the brain. This results in increasing the activity of the protein kinase RNA-like endoplasmic reticulum
kinase PERK/eIF2α-P pathway of the unfolded protein response (UPR), which in turn leads to the
inhibition of protein synthesis. According to a recent study the small-molecule integrated stress
response inhibitor (ISRIB) reduces the level of eIF2α-P by activating eukaryotic initiation factor 2B
(eIF2B), a guanine nucleotide exchange factor (GEF) for eIF2α, resulting in enhancement of protein
synthesis based on in vivo study in the cell-based luciferase reporter assay (Sidrauski, C., et al. Elife.
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2013, 2, e00498; Halliday, M., et al. Cell death dis. 2015, 6 (3), e1672.). Herein, ISRIB analogues
were designed and synthesised, focusing on modifications of the central core cyclohexyl ring,
O-arylglycolamide side chains and terminal aromatic rings of the prototype ISRIB molecule (Figure 5).
Synthesis of truncated ISRIB analogues revealed that even subtle modifications have an obvious
impact on activity. Central core ring was also explored, and it was found that its replacement with
1,4-diaminopiperazine and 1,4-diaminopiperdine retained high activity. Furthermore, to assist in
observe ISRIB′s interaction with eIF2B, we designed and synthesised fluorescently label derivative,
considering the most active compound, with a modified aryl ether portion that was then used to
elaborate the fluorescently label compound. The derivatized compound contained a flexible linker
terminating in a 5/6-carboxyfluorescein moiety (Zyryanova, A. F., et al. Science 2018, 359 (6383),
1533–1536).
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7.2. Novel Synthesis of 3-Fluoro and 3,3-Difluoro Substituted β-Lactams: Evaluation as Potential 
Anticancer Agents (P02) 
Azizah Malebari 1,2 and Mary J. Meegan 2 
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Combretastatin A-4 (CA-4), a natural product stilbene, is a potent microtubule-disrupting agent 
that binds at the colchicine-binding site of tubulin. The design, synthesis and biochemical evaluation 
of a series of analogues of the microtubule-destabilising agent CA-4 is described. The monocyclic β-
lactam CA-4 analogues containing halogen substituents at the C-3 position of β-lactam ring were 
synthesized using the Staudinger reaction (Greene, T.F.; et al. J. Med. Chem., 2016, 59, 90–113; 
Malebari, A.M., et al. Eur. J. Med. Chem. 2017, 130, 261–285). Previous investigations described two 
approaches for the construction of 3-fluoro-β-lactams using the ketene-imine condensation or the 
enolate-imine condensation method (Araki, K., et al. Tetrahedron Lett. 1991, 32, 5461–5464). In the 
present work, the synthesis of 3-fluoro and 3,3-difluoro substituted β-lactams was developed easily 
by a convenient microwave assisted Reformatsky reaction using ethyl bromofluoroacetate and ethyl 
bromodifluoroacetate, respectively (Scheme 2). To the best to our knowledge, this is the first report 
of this new synthetic approach for 3-fluoro and 3,3-difluoro β-lactams as CA-4 analogues. The 
reaction was successful with short reaction time compared to the conventional Staudinger reaction, 
with moderate yield and few steps required, and it was demonstrated to be a convenient and facile 
method for the preparation of a variety of 3-fluoro and 3,3-difluoro β-lactams. The 3-fluoro β-lactams 
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Combretastatin A-4 (CA-4), a natural product stilbene, is a potent microtubule-disrupting agent
that binds at the colchicine-binding site of tubulin. The design, synthesis and biochemical evaluation
of a series of analogues of the microtubule-destabilising agent CA-4 is described. The monocyclic
β-lactam CA-4 analogues containing halogen substituents at the C-3 position of β-lactam ring were
synthesized using the Staudinger reaction (Greene, T.F.; et al. J. Med. Chem., 2016, 59, 90–113;
Malebari, A.M., et al. Eur. J. Med. Chem. 2017, 130, 261–285). Previous investigations described two
approaches for the construction of 3-fluoro-β-lactams using the ketene-imine condensation or the
enolate-imine condensation method (Araki, K., et al. Tetrahedron Lett. 1991, 32, 5461–5464). In the
present work, the synthesis of 3-fluoro and 3,3-difluoro substituted β-lactams was developed easily
by a convenient microwave assisted Reformatsky reaction using ethyl bromofluoroacetate and ethyl
bromodifluoroacetate, respectively (Scheme 2). To the best to our knowledge, this is the first report of
this new synthetic approach for 3-fluoro and 3,3-difluoroβ-lactams as CA-4 analogues. The reaction was
successful with short reaction time compared to the conventional Staudinger reaction, with moderate
yield and few steps required, and it was demonstrated to be a convenient and facile method for the
preparation of a variety of 3-fluoro and 3,3-difluoro β-lactams. The 3-fluoro β-lactams (1–8) and
3,3-difluoro β-lactams (9–16) in this series contained the 3,4,5-trimethoxyphenyl ring A, (required
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for potent activity of CA-4), together with various ring B substituents. The structure of β-lactams 6
and 14 was confirmed by X-ray crystallography. Preliminary cell viability studies demonstrated the
antiproliferative effects of these novel compounds, with an IC50 value of 0.153 µM for 6 in MCF-7
human breast cancer cell line.Pharmaceuticals 2019, 12, x FOR PEER REVIEW 18 of 47 
 
 
Scheme 2. Synthesis of 3-fluoro and 3,3-difluoro β-lactams by the microwave assisted Reformatsky 
reaction. Reagents and conditions: (a) Zn dust, (CH3)3SiCl, 40 °C, 2 min, microwave; C6H6, 100 °C, 30 
min, microwave; products obtained as a racemic mixture, one enantiomer represented. 
7.3. The Influence of Fluorination on Aliphatic Lipophilicity (P03) 
Bruno Linclau 
School of Chemistry, University of Southampton, Southampton SO171BJ, United Kingdom; e-mail: 
bruno.linclau@soton.ac.uk 
Fluorination of bioactive compounds is commonly employed in the drug optimisation process, 
given its potential to modulate a range of properties, and its ability to prevent or slow down 
undesired processes such as oxidation and/or acid-catalysed degradation. In this context, aliphatic 
fluorination (as opposed to aromatic fluorination) is receiving increasing interest. Our group is 
interested in investigating how fluorination affects molecular conformation (Bogdan, E., et al. Chem. 
Eur. J. 2015, 21, 11462–11474) and lipophilicity ((a) Linclau, B., et al. Angew. Chem. Int. Ed. 2016, 55, 
674–678 (VIP); (b) Effries, B., et al. J. Med. Chem. 2018, 61, 10602–10618), as well as hydrogen bond 
properties of adjacent functional groups including chiral aliphatic structures and carbohydrates ((a) 
Graton, J., et al. Angew. Chem. Int. Ed. 2012, 51, 6176–6180 (VIP). (b) Graton, J., et al. Chem. Eur. J. 2017, 
23, 2811–2819) and how this impacts on binding affinity ((a) van Straaten, K.E., et al. J. Am. Chem. Soc. 
2015, 137, 1230–1244; (b) N′Go, I., et al. S. Chem. Eur. J. 2014, 20, 106–112). 
The introduction of fluorine on aliphatic (sp3) carbon often leads to a reduction in lipophilicity, 
and is the result of a number of effects including hydrophobic surface and dipole introduction, as 
well as reduction of polarizability. The importance of these opposing effects depends also on a 
number of factors such as absolute lipophilicity and conformational effects, the latter of which can, 
in turn, be very different in water and octanol. 
We developed a convenient 19F NMR-based method for the logP-determination of fluorinated 
compounds, thus not relying on UV-activity, and used this methodology for an extensive study of 
aliphatic lipophilicity based on an alkanol scaffold. 
This presentation will give an overview of these, and other, unpublished findings, and will 
involve an extensive list of aliphatic fluorination motifs. 
7.4. Exploring the Impact of Polymer Size on the Biological Activity of PEG-Haloperidol Conjugates (P04) 
Az Alddien Natfji, Camilla Pegoraro , Kim Watson, Helen Osborn and Francesca Greco 
School of Pharmacy, University of Reading, Whiteknights PO BOX 224 Reading RG6 6AD Berkshire, United 
Kingdom; e-mail: c.pegoraro@student.reading.ac.uk 
Haloperidol (HA) is a well-known antagonist of D2 receptors, clinically used as an antipsychotic. 
Moreover, HA has been shown to be a ligand of different types of receptors (centrally and 
peripherally) including σ receptors, which have a role in the growth and development of different 
types of solid tumours (van Waarde, A., et al., Biochim. Biophys. Acta Biomembr. 2015, 1848, 2703–2714). 
However, HA, as a small molecule, has the ability to permeate across the blood–brain barrier (BBB) 
and, consequently, produces central nervous system (CNS) (extrapyramidal) side effects, which 
limits its peripheral clinical applications. We have previously suggested that conjugating HA to a 
non-biodegradable polymer through a biologically stable linker could minimise or even prevent its 
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Fluorination f bioactive compounds is commonly employed in the drug optimisation process,
given its potential to modulate a range of properties, and its ability to prevent or slow down undesired
processes such as oxidation and/or acid-catalysed degradation. In this context, aliphatic fluorination
(as opposed to aromatic fluorination) is receiving increasing interest. Our group is interested in
investigating how fluorination affects molecular conformation (Bogdan, E., et al. Chem. Eur. J.
2015, 21, 11462–11474) and lipophilicity ((a) Linclau, B., et al. Angew. Chem. Int. Ed. 2016, 55, 674–678
(VIP); (b) Effries, B., et al. J. Med. Chem. 2018, 61, 10602–10618), as well as hydrogen bond properties of
adjacent functional groups including chiral aliphatic structures and carbohydrates ((a) Graton, J., et al.
Angew. Chem. Int. Ed. 2012, 51, 6176–6180 (VIP). (b) Graton, J., et al. Chem. Eur. J. 2017, 23, 2811–2819)
and how this impacts on binding affinity ((a) van Straaten, K.E., et al. J. Am. Chem. Soc. 2015, 137,
1230–1244; (b) N′Go, I., et al. S. Chem. Eur. J. 2014, 20, 106–112).
The introduction of fluorine on aliphatic (sp3) carbon often leads to a reduction in lipophilicity,
and is the result of a number of effects including hydrophobic surface and dipole introduction, as well
as reduction of polarizability. The importance of these opposing effects depends also on a number
of factors such as absolute lipophilicity and conformational effects, the latter of which can, in turn,
be very different in water and octanol.
We developed a convenient 19F NMR-based method for the logP-determination of fluorinated
compounds, thus not relying on UV-activity, and used this methodology for an extensive study of
aliphatic lipophilicity based on an alkanol scaffold.
This presentation will give an overview of these, and other, unpublished findings, and will involve
an extensive list of aliphatic fluorination motifs.
7.4. Exploring the Impact of Polymer Size on the Biological Activity of PEG-Haloperidol Conjugates (P04)
Az Alddien Natfji, Camilla Pegoraro, Kim Watson, Helen Osborn and Francesca Greco
School of Pharmacy, University of Reading, hiteknights PO BOX 224 Reading RG6 6AD Berkshire,
UK; c.pegoraro@student.reading.ac.uk
Halop rido (HA) is a well-known a tagonist of D2 receptors, clinically used as an antipsychotic.
Moreover, HA has been ho n to be a ligand of different typ s f re eptors (centrally d peripherally)
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including σ receptors, which have a role in the growth and development of different types of solid
tumours (van Waarde, A., et al., Biochim. Biophys. Acta Biomembr. 2015, 1848, 2703–2714). However, HA,
as a small molecule, has the ability to permeate across the blood–brain barrier (BBB) and, consequently,
produces central nervous system (CNS) (extrapyramidal) side effects, which limits its peripheral clinical
applications. We have previously suggested that conjugating HA to a non-biodegradable polymer
through a biologically stable linker could minimise or even prevent its diffusion though the BBB while
retaining its biological efficacy (Figure 6). Therefore, conjugation between PEG, a non-biodegradable
polymer, and HA through a carbamate linkage (biologically stable) was developed for the first time by
our group (Heath, F., et al. Polym. Ch. 2016, 7204–7210). In silico and in vitro studies revealed that the
conjugated HA is extremely unlikely to cross the BBB and that it maintains binding activity towards
D2 receptors, but at low level. In the present study, we evaluated the impact of polymer size on the
biological activity of PEG-HA on σ receptors in vitro. In addition to this, molecular docking studies,
in σ and D2 receptors, were performed to understand the effect of conjugation on the binding of HA to
these receptors.
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PEG-HA conjugates, using different sizes of PEG (6000, 2000 Da), were synthetized and
characterised. A two-step synthesis was carried out: first, HA was modified to have an amine
handle that allows conjugation; second, the HA-amine handle was conjugated to NHS-activated PEG.
In vitro cytotoxicity studies, via σ receptors, were performed on MCF-7. The IC50 values of free HA
and PEG-HA conjugates were determined using the MTT assay. In parallel, molecular docking studies
were conducted. The results revealed that conjugating HA to PEG affected its binding to the receptors.
In the case of D2 receptors, the position of PEG-HA inside the pocket was different compared to free
HA while retaining the salt bridge interaction with Asp114, which has been indicated to be essential
for the biological activity. These findings might justify the reduced biological activity observed for
PEG-HA in vitro. Regarding the σ receptors, initial results indicated that conjugating HA to PEG
influenced its binding to these receptors.
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Abstract Quorum sensing (QS) is a cell-to-cell communication mechanism used by bacterial
populations to control virulence traits and resistance mechanisms (Williams, P., et al. Philos. Trans
R SocLond. B Biol. Sci. 2007, 362, 1119–1134). P. aeruginosa has several QS systems, one of which,
the Pseudomonas quinolone system (pqs) uses alkyl-quinolone (AQ)-derived QS molecules. PqsR is
the key regulatory protein responsible for the activation of the pqs system upon interaction with the
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P. aeruginosa ligands (2-heptyl-3-hydroxy-4(1H)-quinolone (PQS) and 2-heptyl-4-hydroxyquinoline
(HHQ)) to drive the upregulation of AQ production (feedback activation) and virulence factors
biosynthesis (Ilangovan, A., et al. PLoS Pathog. 2013, 9(7), e1003508). It has been shown that the
inhibition of the PqsR receptor attenuates bacterial pathogenicity, without affecting bacterial growth
and viability. Our aim was to design, synthesise and evaluate a series of new PqsR inhibitors using
a quinazolinone-derived molecule (SEN016, IC50 3.2 µM) that was found during a high-throughput
screening (HTS) (Figure 7). Replacement of the quinazolinone ring by benzimidazole (SEN089)
enhanced the activity (IC50 0.067 µM). However, further lead optimisation was required to enhance
its biological and physiochemical profile. The co-crystal structure of SEN089 with PqsRLBD was
determined and used to guide the lead optimisation strategy. Herein, we report further SAR analysis
around modifications (R1, R2 and R3) of SEN089, which resulted in a series of novel PqsR inhibitors
with enhanced biological activity and improved physiochemical properties.
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Inverse Agonist Activities, with a Potential Interest against Alzheimer′s Disease (P06)
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Michel Boulouard 3, Sylvie Claeysen 2, Christophe Rochais 1 and Patrick Dallemagne 1
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3 Normandie Université, UNICAEN, INSERM, U1075, GIP CYCERON, COMETE, Caen, France;
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This work describes the conception and synthesis in vitro and in vivo biological evaluation of novel
multi-target directed ligands (MTDL) able to both activate 5-HT4 receptors, block 5-HT6 receptors and
inhibit acetylcholinesterase activity (AChE), in order to exert a synergistic anti-amnesic effect, potentially
useful in the treatment of Alzheimer′s disease (AD). Indeed, both activation of 5-HT4 and blockage
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of 5-HT6 receptors led to an enhanced acetylcholine release, suggesting that it could lead to efficient
restoration of the cholinergic neurotransmission deficit observed in AD. Furthermore, 5-HT4 receptor
agonists are able to promote the non-amyloidogenic cleavage of the amyloid precursor protein (APP)
and to favour the production of the neurotrophic protein sAPPα. Finally, we identified a pleiotropic
compound, [1-(4-amino-5-chloro-2-methoxyphenyl)-3-(1-(3-methylbenzyl)piperidin-4-yl)propan-1-one
fumaric acid salt, which displayed in vivo an anti-amnesic effect in a model of scopolamine-induced
deficit of working memory at a dose of 0.3 mg/kg.Pharmaceuticals 2019, 12, x FOR PEER REVIEW 21 of 47 
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Inflammation is a hallmark of most neurological disorders and the ability to detect, quantify and 
monitor the inflammatory response of the central nervous system (CNS) could have large implication 
for both diagnosis and therapeutic response prediction (V. Wee Yong, Neuroscientist. 2010; 16: 408–
20). Among the different diagnostic modalities suitable to detect neuro-inflammation, plasmatic 
biomarkers can be used, but no reliable and specific plasmatic biomarker of neuro-inflammation has 
been identified to date. Recently, molecular imaging of neuro-inflammation has been developed—
the in vivo detection of a protein, the P-selectin, which is over-expressed at the luminal surface of 
endothelial cells during neuro-inflammation was performed using micro-sized particles of iron oxide 
(MPIO). However, this biosensor cannot be used in humans because of its toxicity. 
Hyper-polarised xenon-129 (HP-129Xe) has recently emerged as a promising biocompatible 
contrast agent to improve sensitivity of MRI, successfully used to acquire images of the human 
pulmonary system (Liburn, D. M. L., et al. J. Magn. Reson. 2013, 7, 173) and brain (Swanson, S. D., et 
al. Magn. Reson. Med. 1997, 38, 695). However, this gas is not specific of a biological target, and 
therefore it has to be vectorised using a molecular host to be a valuable biosensor. Among them, 
cryptophanes showed very good xenon encapsulation properties, leading to a number of in vitro 
studies using HP-129Xe cryptophane-based biosensors reported in the literature since the 2000s 
(Wang, Y., et al. Acc. Chem. Res. 2016, 49, 2179–2187). 
Here, we propose the design and the synthesis of a new biocompatible MRI biosensor composed 
of a cryptophane core able to encapsulate xenon, and a well-characterized P-selectin antibody able to 
selectively bind endothelial P-selectin with high affinity. The two parts will be connected with a linker 
using copper-free click chemistry to afford the desire biosensor (Figure 8). 
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pulmonary system (Liburn, D. M. L., et al. J. Magn. Reson. 2013, 7, 173) and brain (Swanson, S. D., et al.
Magn. Reson. Med. 1997, 38, 695). However, this gas is not specific of a biological target, and therefore
it has to be vectorised using a molecular host to be a valuable biosensor. Among them, cryptophanes
showed very good xenon encapsulation properties, leading to a number of in vitro studies using
HP-129Xe cryptophane-based biosensors reported in the literature since the 2000s (Wang, Y., et al.
Acc. Chem. Res. 2016, 49, 2179–2187).
Here, we propose the design and the synthesis of a new biocompatible MRI biosensor composed
of a cryptophane core able to encapsulate xenon, and a well-characterized P-selectin antibody able to
selectively bind endothelial P-selectin with high affinity. The two parts will be connected with a linker
using copper-free click chemistry to afford the desire biosensor (Figure 8).
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In recent years much effort has been devoted to the design of potent and selective glycosidase 
inhibitors. However, potential candidates often lack of glycosidase selectivity, and non-specific 
inhibitions may lead to severe side-effects. Limiting selectivity issues is a challenge unmet with the 
first generation of inhibitors. 
Sialidases are glycosidases involved in many physiological and pathological functions. Many 
viruses, bacteria and parasites produce this enzyme to cleave sialic acid residues from host cells, 
unmasking membrane receptors for adhesion and invasion (Newstead, S. L.; et al. J. of Biol. Chem. 
2008, 283 (14), 9080–9088). There are several classes of sialidases, some display a unique catalytic site 
(CAT) to cleave the sialosides, whereas others have an additional lectinic site called CBM 
(carbohydrate-binding module), which is an anchoring point for glycans, thus increasing the catalytic 
efficiency of the enzyme (Thobhani, S., et al. J. Am. Chem. Soc. 2003, 125 (24), 7154–7155). These 
sialidases with CAT and CBM are virulence factors common to many protozoal and pathogenic 
bacteria, and are potential therapeutic targets. Furthermore, human sialidases involved in important 
physiological functions do not express CBMs. 
In this work, we developed an alternative approach to the “lock and key concept” to achieve 
high affinities and selectivities for sialidases (Brissonnet, Y., et al. Chem. Eur. J. 2019, 25 (9), 2358–2365). 
Multivalent thiosialosides were designed to bind to both the CAT and the CBM of pathogenic 
sialidases. 
Sialidases from Vibrio cholerae, Trypanosoma cruzi and Streptococcus pneumoniae were produced 
with and without the CBM to determine the importance of dual targeting and the validity of the 
multivalent concept (Figure 9). 
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In recent years much effort has been devoted to the design of potent and selective glycosidase
inhibitors. However, potential candidates often lack of glycosidase selectivity, and non-specific
inhibitions may lead to severe side-effects. Limiting selectivity issues is a challenge unmet with the
first generation of inhibitors.
Sialidases are glycosidases involved in many physiological and pathological functions. Many
viruses, bacteria and parasites produce this enzyme to cleave sialic acid residues from host cells,
unmasking membrane receptors for adhesion and invasion (Newstead, S. L.; et al. J. of Biol. Chem.
2008, 283 (14), 9080–9088). There are several classes of sialidases, some display a unique catalytic
site (CAT) to cleave the sialosides, whereas others have an additional lectinic site called CBM
(carbohydrate-binding module), which is an anchoring point for glycans, thus increasing the catalytic
efficiency of the enzyme (Thobhani, S., et al. J. Am. Chem. Soc. 2003, 125 (24), 7154–7155).
These sialidases with CAT and CBM are virulence factors common to many protozoal and pathogenic
bacteria, and are potential therapeutic targets. Furthermore, human sialidases involved in important
physiological functions do not express CBMs.
In this work, we developed an alternative approach to the “lock and key concept” to achieve high
affinities and selectivities for sialidases (Brissonnet, Y., et al. Chem. Eur. J. 2019, 25 (9), 2358–2365).
Multivalent thiosialosides were designed to bind to both the CAT and the CBM of pathogenic sialidases.
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Sialidases from Vibrio cholerae, Trypanosoma cruzi and Streptococcus pneumoniae were produced with
and without the CBM to determine the importance of dual targeting and the validity of the multivalent
concept (Figure 9).Pharmaceuticals 2019, 12, x FOR PEER REVIEW 23 of 47 
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four isoforms (α, β, γ and δ), the former two isoforms are ubiquitously expressed, whereas PI3K γ 
and δ are found mainly in the haematopoietic system (Schwehm, C., et al. J. Med. Chem. 2017, 60, 1534–
1554). PI3K δ has been identified as an attractive drug target, where it plays a key role in the 
pathogenesis of blood cancer (lymphoma, leukaemia) and autoimmune disease, such as rheumatoid 
arthritis. Selective inhibition of PI3K δ is desired to avoid the side effects associated with the 
inhibition of PI3k α and β, which play a major role in insulin signalling and platelet aggregation. 
Idelalisib is the first approved selective PI3K δ inhibitor for the treatment of chronic lymphocytic 
leukaemia (CLL) and follicular lymphoma (FL). However, idelalisib has demonstrated serious side 
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Inhibition tests of a polyvalent thiosialoside against the representative bacterial, parasitic and
fungal sialidases showed inhibitory activity up to the nanomolar range with a strong synergistic
effect. These results extend the multivalent concept to this important class of enzymes for which
transition-state inhibitors failed to reach the submicromolar level.
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Phosphatidylinositol-3-kinases (PI3Ks) are lipid kinases that regulate a plethora of cellular
processes including proliferation, survival and motility. PI3Ks have been divided into three classes.
Of these, the most characterized is the class I enzymes, which are activated by cell surface receptors to
generate phosphatidylinositol-3,4,5-trisphosphate (PIP3). Class I PI3Ks are further divided into four
isoforms (α, β, γ and δ), the former two isoforms are ubiquitously expressed, whereas PI3K γ and δ
are found mainly in the haematopoietic system (Schwehm, C., et al. J. Med. Chem. 2017, 60, 1534–1554).
PI3K δ has been identified as an attractive drug target, where it plays a key role in the pathogenesis of
blood cancer (lymphoma, leukaemia) and autoimmune disease, such as rheumatoid arthritis. Selective
inhibition of PI3K δ is desired to avoid the side effects associated with the inhibition of PI3k α and β,
which play a major role in insulin signalling and platelet aggregation. Idelalisib is the first approved
selective PI3K δ inhibitor for the treatment of chronic lymphocytic leukaemia (CLL) and follicular
lymphoma (FL). However, idelalisib has demonstrated serious side effects involving hepatic toxicity,
colitis, serious diarrhoea and pneumonitis (Somoza, J., et al. J. Biol. Chem. 2015, 290, 8439–8446).
Starting from a non-selective PI3K inhibitor “pictilisib”, we identified a series of potent indole-based
inhibitors of PI3K δwith good selectivity versus other PI3K isoforms—the high δ selectivity of these
compounds could be attributed to favourable interaction with “tryptophan shelf”. The “tryptophan
shelf” defines the face of Trp760, that can be accessed only in PI3K δ due to movement of Thr750.
On the other hand, in the other isoforms, the face of the tryptophan is “blocked” by basic residues that
can form strong -cation interactions with Trp760 (Figure 10).
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ecline in discovery of novel antimicrobial comp unds over the last two decades has become
a worldwide problem (Spellberg, B., t al. Clin. Infect. Dis., 2004, 38(9), 1279–1286). With the ability
of micr organisms to evolve and adapt to survive exposure to antibiotics, that is, the emergence of
antimicrobial resistance (AMR), human health is severely threatened (O′Neill, J.; 2014 (Accessed: May
2019)). For instance, AMR hampers the treat ent of post-surg ry infections caused by bacteri such as
Staphylococ us ureus, and severely complicate the healing of infected chronic wounds.
Previous work in our group showed that amino acid-functionalised dehydroabietic acid derivatives
are capable of killing planktonic bacteria and limit their ability to form biofilms (a. Manner, S., et al.
Eur. J. M d. Chem. 2015, 102, 68–79; b. Helfenstein, A., et al. Bioorg. Med. Chem, 2017, 25, 132–137;
c. Fallarero, A., et al. Int. J. M ol. Sci. 2013, 14, 12054–12072). This is particularly elevant, as biofilms’
contribution to AMR are highly resilient to traditional antimicrobials (a. Manner, S., et al. Eur. J.
Med. Chem. 2015, 102, 68–79; b. Helfenst in, A., et l. Bioorg. Med. Chem, 2017, 25, 132–137;
c. Fallarero, A., et al. Int. J. Mol. Sci. 2013, 14, 12054–12072). The group has also shown that the
functionalisation of nanocellulose with the abietane dehydroabieylamine resulted in innova ive and
cost-efficient eco-friendly surfaces ith antimicrobial properties and good biocompatibility (Hassan,
G, et al. ACS Sust. Chem. Eng., 2019, 7, 5002–5009). As the p imary structural co onent of the pl t
cell wall, cellulose is the most common organic compound on the planet. It can be harvest d and
processed from many differen renewable pla t sources such as wood and cotton (a. Schultz, C., et al.
ACS Sustainable Chem. Eng., 2018, 67, 8317–8324; b. Lin, N., et l. Molecules, 2018, 23(10), 2684–2708).
This combination of renewability, low cost, strong structural integrity and its innate non-cytotoxic
properties m ke it an ideal basis for development of new antimicrob al biomaterials.
The goal of our current work is to build from this knowledge and che ically modify medically
relevant bi polymers with our in-house library of antimicrobial abietanes to produce materials with
innate ant bacterial properties a d explore their potential applications in w und-healing.
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Combretastatin A-4 (CA-4) is the most potent antimitotic agent of the combretastatin A series,
a group of diaryl stilbenes isolated from the wood of the South African tree Combretum caffrum
(Watt, J. M., et al. The Medicinal and Poisonous Plants of Southern and Eastern Africa. E. & S. Livingstone
Ltd.: Edinburgh and London, United Kingdom, 1962). It has significant anticancer activity through
inhibition of tubulin polymerization and microtubule assembly (Pettit, G. R., et al. Experientia
1988, 45). While cis stilbene structures demonstrate superior biological activity, the corresponding
trans derivatives are inherently more stable. Isomerization of cis CA-4 to the trans form is observed
both during storage and in vivo during metabolism, which dramatically reduces anti-tumour activity
(Ohsumi, K., et al. Bioorg. Med. Chem. Lett. 1998, 8, 3153–3158). Our group previously employed
the Staudinger reaction to synthesize novel 3-hydroxy-1,4-diaryl-2-azetidinones. The problem of
CA-4′s cis–trans isomerization has been overcome via chemical manipulation of CA-4′s alkene bridge,
utilizing a β-lactam ring to induce cis restriction. A number of analogues (Figure 11) have shown
potent nanomolar antiproliferative activity in MCF-7 and HL-60 cells with enhanced activity relative to
CA-4 (O′Boyle, N. M., et al. J. Med. Chem. 2010, 53, 8569; Azizah, M., et al. Eur. J. Med. Chem. 2017, 130,
261–285). Typical Staudinger reactions form mixtures of cis and trans isomers depending on reaction
conditions employed, and additionally, at the 3-hydroxy position′s chiral center, racemic mixtures
of R&S enantiomers. Trans isomers of 3-substituted-2-azetidinones have been shown to be up to
50 times more potent than the corresponding cis derivatives emphasizing the requirement to optimize
the Staudinger approach to minimize yields of the undesirable cis isomer. Levo- and dextro-rotatory
enantiomers hold potential to display lesser or greater biological activity relative to one another.
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Our current work aims to (1) improve the available yield for chiral resolution
by determini g the necessary conditions to chiev ste eoselective synthesis of tra s
3-hydroxy-1,4-diaryl-2-azetidinones in the Staudinger reaction and (2) provide purification of r cemic
mixtures using N-(ter -butoxyca bonyl)-L-Proline as a chiral resolving agent to afford optically pure
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enantiomers for further biological evaluation. Trans 3-hydroxy β-lactams have been separated from
cis derivatives using chromatographic purification. We have since optimized the Staudinger reaction
to return relative yields of 95% relative ratio of trans/cis isomers, as indicated by integration of
protons at position 3 and 4 of the β-lactam on 1H-NMR. Diastereomeric resolution using flash column
chromatography followed by hydrolysis of chiral resolving agents successfully yielded enantiomers of
EMCL001 and 2 (Figure 11). Preliminary biochemical data for the enantiomers in breast cancer cells
will be reported.
7.12. Promising Biologically Active Peptides of Hirudo medicinalis (P12)
Ekaterina Grafskaia 1,2, Kirill Nadezhdin 2,3, Irina Talyzina 3,4, Nadezhda Polina 1, Oleg Podgorny 1,5,
Pavel Bobrovsky 1, Ivan Latsis 1, Valentin Manuvera 1,2 and Vassili Lazarev 1,2
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Agency, 119435 Moscow, Russia
2 Moscow Institute of Physics and Technology (State University), 141701 Dolgoprudny, Russia
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Sciences, 117997 Moscow, Russia
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University (Lomonosov MSU or MSU), 119991 Moscow, Russia
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Our previous research aimed at complete genome sequence of medicinal leech Hirudo medicinalis,
allowing for in silico implementation of the searching algorithms to identify new biologically active
peptides, such as thrombolytic, anticoagulant and antibacterial agents. We applied computational
algorithms to the medicinal leech Hirudo medicinalis genome assembly and identified homologs of
serine proteinase inhibitors, promising anticoagulant proteins and candidate antimicrobial peptides
(AMPs). Identified AMPs were chemically synthesised and assayed antimicrobial activity against three
bacterial species (Escherichia coli, Bacillus subtilis and Chlamydia thrachomatis), cytotoxic and hemolytic
activities and determined their secondary structures by NMR spectroscopy. Eight peptides exhibited
antimicrobial activity, and two peptides, 3967 and 536–1, reduced the survival of E. coli, B. subtilis and
C. thrachomatis cells through the disruption of cellular integrity at a concentration of 10 µM. Almost all
the examined AMPs exhibited low-to-moderate haemolytic activity with no effects on the viability of
cultured eukaryotic cells. Moreover, it was shown that three peptides, 536_2, 12530 and 3967, adopted
α-helical conformation in membrane-mimetic DPC micelles. Overall, our experimental data verify the
utility of the developed computational algorithms for the discovery of potential biologically active
peptides. Using developed computational algorithm, we identified two promising medicinal leech
AMPs, 3967 and 536–1, which are able to be considered in perspective as therapeutic agents.
This work was supported by the Russian Science Foundation (project№17–75–20099).
7.13. Subtype-Selective Fluorescent Ligands as Pharmacological Tools for the Human Adenosine hA2A AR
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The last decades have witnessed a significant growth and development of fluorescence-based
techniques as a means to facilitate understanding of the signalling and dynamics of drug targets such
as G protein-coupled receptors (GPCRs) in their native cellular environment (Vernall, A. J, et al. Br. J.
Pharmacol. 2014, 171 (5), 1073–1084; Stoddart, L. A., et al. Sci. Rep. 2018, 8 (1), 1–19). Among the class
A GPCRs, the human adenosine hA2AAR receptor represents an attractive drug target, which has
been the subject of intensive medicinal chemistry research during the last 40 years due to the broad
tissue distribution and implication in modulating a variety of biological processes (Ruiz, M., et al.
J. Med. Chem. 2014, 57, 3623–3650). The hA2AAR mainly signals through the stimulatory GPCR and,
upon receptor activation, adenyl cyclase is stimulated, leading to Cyclic adenosine monophosphate
cAMP accumulation. The therapeutic potential of targeting the hA2AAR has been broadly investigated,
leading to the development of an extensive number of synthetic agonists and antagonists for the
treatment of several diseases including cardiovascular, inflammatory and CNS disorders. More
recently, targeting the hA2AAR has generated a great interest in cancer immunotherapy. The tumour
micro-environment features high concentrations of immunosuppressive adenosine that, upon A2AAR
engagement, silences the immune response in the host, leading to tumour growth and proliferation.
Indeed, A2AAR antagonism is being investigated as a therapeutic approach to defeat the immune
system evasion by the tumour (Leone, R. D., et al. J. Immunother. Cancer 2018, 6 (1), 1–9). In this regard,
understanding the complexity of the adenosinergic signalling is an essential prerequisite to address and
develop more efficacious therapies. This can be facilitated by exploiting fluorescent probes selectively
targeting the hA2AAR both in vitro and in vivo (Vernall, A. J., et al. iScience 2018, 6, 280–288).
Herein, we report the design synthesis and pharmacological evaluation of two generations of
subtype-selective fluorescently-labelled hA2AAR antagonists based on preladenant. Of particular
interest for in vivo studies was the second generation of ligands, which features water soluble probes
and, therefore, might display better stability in plasma and improved detection after IV-administration.
Molecular modelling analysis has corroborated previously reported SAR studies indicating the optimal
position for fluorophore attachment. The newly synthesised fluorescent probes retained functional
activity and binding affinity at the hA2AAR, displaying a selectivity of >1000 nM over the other
receptor subtypes. The effectiveness of the probes as pharmacological tools was also investigated
in high resolution confocal imaging studies, revealing specific co-localisation with SNAP-hA2AAR
at the cell membrane, which was surmounted by incubating the cells with high concentration of
unlabelled ligand. In conclusion, given their excellent pharmacological and photochemical properties,
the reported novel fluorescent ligands embody valuable tools to study the signalling and dynamics of
the hA2AAR, not only in vitro but also in vivo, providing a robust and specific platform for further
drug discovery investigations.
7.14. Synthesis and Pharmacological Evaluation of 5,6,7,8-Tetrahydroimidazo[1–a]Pyrazine-Based
Thiosemicarbazones against Trypanosoma cruzi (P14)
Marlene S. de Araújo Neta 1,2, Felipe N. Coutinho 1,2, Antônio R. de Faria 2, Carine Picot 1,
Fabrice Pagniez 1, Patrice Le Pape 1, Teresinha G. da Silva 3 and Pascal Marchand 1
1 Université de Nantes, Cibles et médicaments des infections et du cancer, IICiMed, EA 1155, F-44000
Nantes, France
2 Department of Pharmaceutical Sciences, University of Pernambuco, Recife-PE 50740–520, Brazil
3 Department of Antibiotics, University Federal of Pernambuco, Recife-PE 50740–520, Brazil;
pascal.marchand@univ-nantes.fr
Neglected tropical diseases (NTDs) affect mainly underdeveloped or developing countries located
in Africa, Asia and Latin America. Worldwide, there are more than one billion people affected by these
diseases (World Health Organization, Neglected Tropical Diseases. Access: 26 May 2017. Information
site: http://www.who.int/neglected_diseases/diseases/en/). These include Chagas disease, also known
as American trypanosomiasis, a potentially life-threatening illness caused by the protozoan parasite
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Trypanosoma cruzi (T. cruzi). Difficulty of treatment due to the amount of side effects of the drugs
currently used, the resistance of the parasite and late detection are concerns to address. Therefore,
the discovery of new substances for the treatment of Chagas disease is extremely necessary. Thus, we
developed a medicinal chemistry program dealing with the synthesis of 5,6,7,8-tetrahydroimidazo
[1, 2-a] pyrazine-based thiosemicarbazones as antiparasitic agents (Moreno-Rodríguez, A., et al. Eur. J.
Med. Chem. 2014, 87, 23–29; Leite, F., et al. Eur.J. Med. Chem. 2016, 123, 639–648; Marchand, P., et al.
Eur.J. Med. Chem. 2015, 103, 381–395.) (Figure 12).
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Myeloid leukemias are myeloproliferative diseases that affect hematopoietic stem cells (HSC),
and are divided in two types acute (AML) and chronic (CML) according to a fast or slower cell growth.
CML is mainly due to the t(9,22) genomic translocation-derived BCR-ABL fusion oncogene coding
for the tyrosine kinase Bcr-Abl, which activates the transcription factors STAT5 (signal transducers and
activators of transcription 5). The latter plays a crucial role in the initiation and maintenance of CML
and mediates resistance to Bcr-Abl kinase inhibitors such as imatinib mesylate (IM, Glivec) (Hoelbl
et al. EMBO Mol. Med. 2010, 2, 98–110; Kavalerchik, et al. J. Clin. Oncol. 2008, 26, 2911–2915). AML
results mainly from internal tandem duplication (Itd) mutations in the juxtamembrane region or point
mutation in fms like tyrosine kinase 3, FLT3. This oncoprotein FLT3-Itd (internal tandem duplication)
has a tyrosine kinase activity, which activates STAT5 (Birkenkamp, et al. Leukemia 2001, 15, 1923–1931).
As a result, inhibiting STAT5 would contribute to reduce the survival of CML and AML cells and
moreover tackle their potential chemoresistance.
A first structure–activity relationship study allowed us to identify one compound, 17f (Figure 13),
which inhibited the growth of AML and CML cell lines as well as phosphorylation and transcriptional
activity of STAT5. These results suggest that 17f might be a new lead molecule targeting STAT5
signalling in myeloid leukemias (Juen, et al. J. Med. Chem. 2017, 60, 6119–6136). Thanks to these results,
synthesis of 17f new analogues with modulation around the tetrahydroquinoleine (THQ) ring were
undertaken and their biological evaluation was carried out on model CML (KU812, K562) and AML
(MV-4–11) cell lines. Among these new results, one compound, with the 4-pyridinyl in position 5 on
the THQ ring, showed slightly better results than 17f on all cell lines. This outcome will guide further
modulation work on the THQ ring with others nitrogen heterocycles (pyridazine, triazine, etc.).
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7.16. From Phloridzin towards Semisynthetic Bioactive Dihydrochalcones (P16)
A. Cala Peralta 1, F. Mayr 2, G. Viault 1, V. Temml 2, D. Schuster 3, H. Stuppner 2, D. Séraphin 1,
P. Richomme 1 and J-J. Hélesbeux 1
1 SONAS, EA921, UNIV Angers, SFR QUASAV, Faculty of Health Sciences, Department of Pharmacy,
16 bd Daviers, 49045 Angers Cedex 01, France
2 Institute of Pharmacy/Pharmacognosy and Center for Molecular Biosciences Innsbruck (CMBI),
University of Innsbruck, 6020 Innsbruck, Austria
3 Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, Paracelsus Medical
University Salzburg, 5020 Salzburg, Austria; jj.helesbeux@univ-angers.fr
Plant secondary metabolism produces a large number of specialized compounds (over 300,000)
including terpenoids, alkaloids and (poly)phenols. Often referred to as “natural products” (NPs),
many of these compounds are used for medicinal, cosmetical and/or nutraceutical purposes. Apple
trees (Malus x domestica Brokh.) are widely cultivated all around the world, and apple is the first fruit
to be produced in Europe. In France, the “Région des Pays de la Loire” appears as the second national
producer of apples, with apple trees being the main cultivated surface in this area. Apple fruits/trees
are characterized with a cell specific accumulation—in different tissues—of varying levels of bioactive
polyphenols including proanthocyanidins, anthocyanins, flavonols and dihydrochalcones (DHCs)
(Figure 14).
Table 1. General structure of the compounds.
Compound R1 R2 R3
Phloretin (Pt) OH OH H
Phlorizin OH OGlu H
3-Hydroxyphloretin
(HPt) OH OH OH
Trilobatin OGlu OH H
Sieboldin OGlu OH OH
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To date, around 250 DHCs are known, either as glycosylated derivatives or C-alkylated compounds
(C. Rivière in Studies in Natural Products Chemistry, 2016, 51, 253–281). Amongst the latter, some
C-benzylated compounds have demonstrated significant pharmacological effects (anti-inflammatory,
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anti-tumoral) (Somsrisa, J., et al. Molecules 2013, 18, 6898–6907; Prawat, U., et al. Planta Med. 2013, 79,
83–86). Therefore this series of compounds is of high interest because of their pharmacological potential.
The main goal of this project is to (semi-)synthesize original DHCs, in particular, C-benzylated
derivatives, starting from phloridzin or sieboldin extracted from locally produced apple tree leaves
as renewable sources. The semi-synthetic analogues will then be submitted to biological assays to
evaluate their anti-tumoural potential.
7.17. Synthesis and Pharmacological Study of Alprenolol Analogues at the Secondary Conformation of the
β1-Adrenoceptor (P17)
Emanuel P. Sousa 1,2, Peter J. Scammells 3, Jillian G. Baker 2 and Shailesh N. Mistry 1
1 School of Pharmacy, Centre for Biomolecular Sciences, University of Nottingham, Nottingham NG7
2RD, UK
2 Cell Signalling, School of Life Sciences, Queen′s Medical Centre, University of Nottingham,
Nottingham NG7 2UH, UK
3 Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 3052 Victoria,
Australia; emanuel.pintodesousa@nottingham.ac.uk
The β1-adrenergic receptor (β1-AR) exists in at least two distinct agonist conformations: (1) a
primary conformation where responses are readily inhibited by antagonists and (2) a secondary
conformation of which the precise nature is unknown, where agonist responses are relatively resistant
to antagonism (Kaumann, A.J., et al. Pharmacol. Ther. 2008, 118, 303–336).
Endogenous catecholamines (e.g., adrenaline) and conventional agonists (e.g., isoprenaline and
cimaterol) mediate a response mainly through the primary conformation. Other ligands (e.g., CGP12177
1) mediate a response through the secondary conformation, even though the concentration required to
stimulate this response is considerably greater than the concentration required to bind the primary
conformation (Pak, M.D., et al. J. Recept Signal Transduct Res., 1996, 16, 1–23). Alprenolol (2) stimulates a
response through both conformations and it also requires higher concentrations to activate the secondary
conformation (Baker, J.G., et al. Mol. Pharmacol, 2003, 63, 1312–1321). To date, no ligand has been
reported that binds the secondary conformation with higher affinity than the primary conformation.
Alprenolol bis analogue 3 has been previously identified as the first sub-micromolar compound to
have similar affinity for both conformations (Sousa, E.P, et al. 2018, Poster presented at EFMC-ISMC
2018). In order to identify the molecular descriptors responsible for the interaction and activation of
the secondary conformation of the β1-AR, several analogues were synthesised and pharmacologically
characterised through competitive radioligand binding assays and cAMP reporter gene (CRE-SPAP)
functional assays. In this communication, we report the affinity of these analogues for both
conformations of the β1-AR.
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2 Moscow Institute of Physics and Technology (State University), 141700 Moscow, Russia
3 Institute of Problems of Chemical Physics of RAS, 142432 Chernogolovka, Russia
4 Institut de Science de Matériaux de Mulhouse (IS2M-CNRS), F-68057 Mulhouse, France;
kseniya.grafskaya@phystech.edu
Aqueous microgels based on poly(N-vinylcaprolactam) with reversable temperature-induced
volume transition are promising “smart” materials for various applications, in particular for drug
delivery (Saunders, B. R., et al. Adv. Colloid. Interfac. 2009, 147–48, 251–262). Here, the aqueous
microgels are modified via acid–base interaction by ligand molecules. They are wedge-shaped
amphiphilic sulfonic acid molecules with an azobenzene grou and alkyl chains of different lengths.
Modified microgels remain colloidally stabile in water and show different responses to the change of
temperature and pH within the physiologic condition (Grafskaia, K. N., et al. Chem. Commun. 2017, 53,
13217). The hydrophobicity of the microgel interior increases with the increase of the modification
degree. Hardening of hydrophobic nanodomains and a decrease of the hydrodynamic diameter
for sample complexed with C8AzoSO3H at the highest neutralization degrees can be explained by
formation of the alkyl sub-lattice (Figure 15).
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7.19. DYRK2 Inhibition—A Potential Targeted Therapy for TNBC (P19) 
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Triple negative breast cancer (TNBC) is the most aggressive form of breast cancer. It accounts 
for approximately 20% of all breast cancers and has an increased rate of relapse compared to non-
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Figure 15. GIWAXS curves of PVCL/AAEM/VIm/(C8AzoSO3H) microgels with DN = 25 (red), 50 (green)
and 100% (black) (left); GIWAXS pattern of PVCL/AAEM/VIm/(C8AzoSO3H) microgels with DN = 25
(right).
The characterisation of local structure of microgels was performed by GIWAXS technique.
In wide-angle region, a narrow reflection corresponding to d-spacing of 4.82 Å can be clearly
seen. One can assume that this peak originated from the linear alkyl chain packing of the
wedge-shaped mesogens (Zhu, X. M., et al. Phys. Chem. Chem. Phys. 2010, 12, 1444–1452;
Grafskaia, K. N., et al. Chem. Commun. 2017, 53, 13217). Formation of alkyl sub-lattice can explain
hardening of hydrophobic nanodomains and decrease of hydrodynamic diameter for the sample
PVCL/AAEM/VIm/(C8AzoSO3H)100%.
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Triple negative breast cancer (TNBC) is the most aggressive form of breast cancer. It accounts for
approximately 20% of all breast cancers and has an increased rate of relapse compared to non-TNBCs.
This aggressive nature is due to its lack of receptors for targeted therapies and thus results in
chemotherapy being the only option for treatment (Gonçalves Jr, H., et al. Clin. Med. In. Onc.
2018, 12, 1–10). This reveals the need to investigate other means for targeting and treating TNBC,
more specifically, through the use of small molecule inhibitors. We discovered that dual specificity
tyrosine(Y) regulated kinase-2 (DYRK2) stabilises heat shock factor-1 (HSF1), the master regulator
of proteotoxic stress pathways (Rashmi, K. C., et al. Cell Stress and Chaperones, 2017, 22, 751–766).
In addition, we showed that low DYRK2 expression correlates with an increased survival rate in TNBC
patients (Figure 16A).
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To date, there are no selective small molecule inhibitors for DYRK2. With the aid of molecular 
modelling, we developed an SAR profile of DYRK2 inhibitors, with our most potent inhibitor being 
LB35 Ki 19 nM (Figure 16B). These inhibitors revealed an impressive selectivity profile, whereby a 
structurally similar compound showed <30% inhibition against a panel of 40 structurally related 
kinases. Within this poster, we aim to describe our ongoing efforts to provide an inhibitor for DYRK2 
with increased potency and examine the DMPK challenges associated with this inhibitor series. 
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The loss of a ligand′s entropy upon receptor binding can be reduced by rigidification of its 
chemical structure, often leading to enhanced potency, depending on whether the bioactive 
conformation is matched or not. Conformational restriction can also induce selectivity for receptor 
subtypes, as slightly different shapes of orthosteric binding pockets may require a different 
conformational adaption of the ligand. Taking advantage of those effects can lead to the development 
of novel molecular probes for scientific research and medications with improved pharmacodynamic 
or pharmacokinetic properties (Ring, et al. Nature. 2013, 502, 575–579). 
Using the pharmacologically important target β2-AR, we aimed at synthetically constraining 
highly flexible agonists of the catecholamine type into their bioactive conformation. Thus, we 
synthesized a set of eight different isomers of ethylene bridged isoprenaline, with one of them 
(“super-iso”) being clearly superior regarding affinity, potency and selectivity for β2 over β1. Super-
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The of a ligand′s entropy upon receptor binding can be reduced by rigidification of i s chemical
structure, often leading to enha ced potency, dependi g on whether the bioactiv conformation is
matched or ot. Conformational restriction can lso induce selectivity for re ptor subtypes, as slightly
different shapes of orthost ic binding pockets may require a different conformational adaption of the
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ligand. Taking advantage of those effects can lead to the development of novel molecular probes for
scientific research and medications with improved pharmacodynamic or pharmacokinetic properties
(Ring, et al. Nature. 2013, 502, 575–579).
Using the pharmacologically important targetβ2-AR, we aimed at synthetically constraining highly
flexible agonists of the catecholamine type into their bioactive conformation. Thus, we synthesized a
set of eight different isomers of ethylene bridged isoprenaline, with one of them (“super-iso”) being
clearly superior regarding affinity, potency and selectivity for β2 over β1. Super-epi, super-norepi, etc.,
refer to compounds with the same constitution and stereochemical configuration (Figure 17).
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Figure 17. Illustration of the ß2-AR active state crystal structures in complex with either epinephrine 
or super-epi, which were shown to occupy virtually the same binding pocket in the receptor. 
Structural insights into the receptor state and the binding poses of super-epi and super-iso were 
obtained by co-crystal structures of β2-AR bound to Nb6B9. 
The poster will also give information about efficient chemical synthesis, biological investigations 
and structure–activity relationships (SAR) of the conformationally restricted catecholamines. 
7.21. Synthesis of Lung Tissue Retentive Prodrugs (P21) 
J. Ayre  1, D. Speed 1, R. Weaver 2, G. Vitulli 3, J. Morrell 3, C. Bosquillon 1, J. M. Redmond 1 and M. 
J. Stocks 1 
1 School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD. 
2 XenoGesis, BioCity, Pennyfoot Street, Nottingham NG1 1GF.  
3 DMPK, GSK, Gunnels Wood Rd, Stevenage, Hertfordshire SG1 2NY.  
4 Chemical Biology, GSK, Gunnels Wood Rd, Stevenage, Hertfordshire SG1 2NY; emails: 
jack.ayre@nottingham.ac.uk, michael.stocks@nottingham.ac.uk*, joanna.m.redmond@gsk.com 
The pulmonary drug delivery route possesses significant benefits over other administrative 
routes, including targeted delivery to the site of action, by-pass of first pass metabolism in the liver 
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describes the design and synthesis of a range of dibasic prodrugs that have the potential to be 
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active drug at a slower more consistent rate. 
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Breast cancer is the most common cancer in women, resulting in 2.09 million cases worldwide 
(WHO Fact Sheets https://www.who.int/en/news-room/fact-sheets/detail/cancer (12 Sepetmber 
2018). Flavones are one of the most active classes of flavonoids exhibiting anti-tumour activities. 
Flavopiridol, for example, has reached phase-II clinical trials as an anti-cancer agent against 
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Structural insights into the receptor state and the binding poses of super-epi and super-iso were
obtained by co-crystal structures of β2-AR bound to Nb6B9.
The poster will also give information about efficient chemical synthesis, biological investigations
and structure–activity relationships (SAR) of the conformationally restricted catecholamines.
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The pulmonary drug delivery route possesses significant benefits over other administrative routes,
including targeted delivery to the site of action, by-pass of first pass metabolism in the liver and fewer
side effects owing to a reduced drug dosage. However, rapid drug elimination from lung tissue in to
the hepatic vein and the pan antagonistic nature of receptor antagonists often leads to increased side
effects. By exploiting the highly lung retentive nature of dibasic compounds, it is possible to reduce
the rate of elimination from the lungs and thus reduce side effects. This work describes the design
and synthesis of a range of dibasic prodrugs that have the potential to be lysosomally trapped within
lung tissue and cleave slowly at a desired pH to effectively deliver an active drug at a slower more
consistent rate.
7.22. Design and Synthesis of Novel Flavone Derivatives as Anti-Cancer Agents (P22)
Mai Khater, Francesca Grecoa and Helen M.I. Osborna
School of Pharmacy, University of Reading, Reading RG6 6AD, UK; m.a.a.khater@pgr.reading.ac.uk
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Breast cancer is the most common cancer in women, resulting in 2.09 million cases worldwide
(WHO Fact Sheets https://www.who.int/en/news-room/fact-sheets/detail/cancer (12 Sepetmber 2018).
Flavones are one of the most active classes of flavonoids exhibiting anti-tumour activities. Flavopiridol,
for example, has reached phase-II clinical trials as an anti-cancer agent against leukaemia, lymphoma
and solid tumours. Selenium and ruthenium atoms have demonstrated promising anti-proliferative
activities when incorporated into small molecular ligands (Olla S., et al. Bioorg. Med. Chem. Lett.
2009, 19, 1512–1516). Replacement of flavonoids′ oxo-carbonyl with a seleno-carbonyl can result in up
to a 25-fold decrease in IC50 values on breast cancer cell lines (Martins I. L., et al. J. Med. Chem. 2015, 58,
4250–4256) (Scheme 3). On the other hand, coordination with metal atoms such as ruthenium is reported
to enhance flavonoids′ water solubility up to 10-fold, which can lead to better clinical applications.
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Venkataraman rearrangement pathway.. This will be followed by in vitro cytotoxicity and anti-
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According to a recent report from the World Health Organization (WHO), leishmaniases—
visceral leishmaniasis (VL), cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL)
—collectively affect 12 million people in 98 countries, 350 million more are at risk of infection and
40,000 deaths are attributed to leishmaniases each year. Currently, there are no effective vaccines and
a number of drugs are used in the treatment of these parasitic infections: pentavalent antimonials,
amphotericin B, miltefosine, pentamidine, paromomycin and sitamaquine (Sangshetti, J.N., et al.
RSC Adv. 2015, 5, 32376–32415). Unfortunately, most of them cause side effects and high toxicities,
and an inevitable resistance has developed in recent times in Leishmania parasites. Consequently,
there is an urgent need to speed up the development of a new generation of more effective and
safe antileishmanials.
In the course of our ongoing synthetic and screening programs for the obtention of new biologically
active imidazo [1, 2-a] azines, we decided to develop bioisostere analogues of the previously described
2,3-diarylimidazo[1,2-a]pyridines as antileishmanial agents (Marhadour, S., et al. Eur. J. Med. Chem.
2012, 58, 543–556).
Two promising analogues were highlighted as hit compounds (Figure 18), exhibiting very good
in vitro and in vivo activity associated with high therapeutic index, especially on amastigote stage of
the parasite (Marchand, P., et al. Eur. J. Med. Chem. 2015, 103, 381–395).
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The X-linked inhibitor of apoptosis protein (XIAP) binds to and inhibits caspases 3, 7 and 9, 
which are some of the enzymes responsible for cell death, and therefore stopping apoptosis. XIAP is 
naturally regulated (inhibited) by the mitochondrial protein SMAC/DIABLO. However, XIAP is 
overexpressed in tumorous cells (particularly in ovarian cancer) making them resist cell death. This 
is why XIAP makes a suitable drug target. 
The project aims at designing new non-peptidic inhibitors of XIAP in order to promote apoptotic 
cell death in ovarian tumours. This could be done by “mimicking” the AVPI tetra-peptide of SMAC 
(β strand) that is used by the latter to bind to the BIR3 domain of XIAP. 
First, a pharmacophore model was built on the basis of two ligands of XIAP-BIR3 found in the 
literature. Then, a series of compounds were designed. The binding of these compounds to the active 
site was studied by molecular docking. Molecular dynamics simulations were then performed to 
assess the stability of the ligands in the active site. The best compounds were synthetized and tested 
in-vitro by fluorescence polarisation assay (FPA). The most promising candidates were selected in 
order to carry out new pharmacomodulations. 
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Figure 18. Structures of hit compounds.
The mechanism of action involved in the antiparasitic properties will be discussed, as 4-pyridyl
moiety at the C-3 position of the heterocyclic core was associated with L. major casein kinase 1
(LmCK1) inhibition, validated as a potential molecular target for antileishmanial drug development
(Durieu, E., et al. Antimicrob. Agents Chemother. 2016, 60, 2822–2833).
7.24. Inhibiting X-Linked Inhibitor of Apoptosis Protein (XIAP), Design of New Non-Peptidic Foldamers of
SMAC (P24)
Meziane Yahia-Ouahmed, Martin Giret, Kévin Antraygues, Marie Jouanne, Charline Kieffer and
Jana Sopkova-de Oliveira Santos
Normandie Univ, UNICAEN, EA 4258 CERMN—FR CNRS INC3M, Caen, France
The X-linked inhibitor of apoptosis protein (XIAP) binds to and inhibits caspases 3, 7 and 9, which
are some of the enzymes responsible for cell death, and therefore stopping apoptosis. XIAP is naturally
regulated (inhibited) by the mitochondrial protein SMAC/DIABLO. However, XIAP is overexpressed
in tumorous cells (particularly in ovarian cancer) making them resist cell death. This is why XIAP
makes a suitable drug target.
The project aims at designing new non-peptidic inhibitors of XIAP in order to promote apoptotic
cell death in ovarian tumours. This could be done by “mimicking” the AVPI tetra-peptide of SMAC
(β strand) that is used by the latter to bind to the BIR3 domain of XIAP.
First, a pharmacophore model was built on the basis of two ligands of XIAP-BIR3 found in the
literature. Then, a series of compounds were designed. The binding of these compounds to the active
site was studied by molecular docking. Molecular dynamics simulations were then performed to
assess the stability of the ligands in the active site. The best compounds were synthetized and tested
in-vitro by fluorescence polarisation assay (FPA). The most promising candidates were selected in
order to carry out new pharmacomodulations.
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7.25. Discovery of Novel pqs Inhibitors for Pseudomonas aeruginosa Infections (P25)
Rui-Ling Liu 1, Fadi Soukarieh 2, William Richardson 1, Shailesh N. Mistry 1, Miguel Cámara 2 and
Michael J. Stocks 1
1 School of Pharmacy, Nottinghamshire NG7 2RD, UK
2 School of Life Sciences, National Biofilms Innovation Centre, Centre for Biomolecular Sciences,
University of Nottingham, Nottingham, Nottinghamshire NG7 2RD, UK; paxrll@nottingham.ac.uk
Current antibiotic treatments for P. aeruginosa infections have proven ineffective due to the
increasing rate of resistance to them. Inhibitors of the pqs quorum sensing signalling, key for the
control of virulence, have been regarded as a promising alternative (Melissa, S., et al. PLoS. Pathog.
2014, 10, e1004321).
In this work, we report the discovery, design, synthesis and biological evaluation of a series of
novel inhibitors of the PqsR regulatory protein, key for the activation of the pqs system, resulting in
the identification of compound 2. The initial hit compound 1 (IC50 = 0.98 µM) was obtained through
a virtual screening performed on PqsR ligand-binding domain using an in-house compound library
(Figure 19a). Exploration of compound 1 gave the first generation of compounds evaluated using
both PAO1-L mCTX: PpqsA-lux and PA14 mCTX: PpqsA-lux P. aeruginosa pqs bioreporter strains. Further
structure activity exploration, to improve potency and physiochemical properties, gave a second
generation of compounds with improved inhibitory activity. Notably, the introduction of an electron
deficient tail group gave compound 2 (IC50 = 0.25 µM), one of the most potent known pqs inhibitors to
date. The crystallization of compound 2 in PqsR ligand binding domain was obtained (Figure 19b) and
detailed SAR studies of this series of compounds will be discussed in the poster.
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7.26. In Silico Screening and Development of Small Molecule Neurotrophin Receptor Ligands (P26) 
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(UNICAEN), 14000 Caen, France; e-mail: mirjana.antonijevic@unicaen.fr 
Neurodegenerative diseases (ND), such as Alzheimer′s disease, Parkinson′s disease, multiple 
sclerosis and motor neuron disease, are on the rise worldwide. Currently, there is no cure for any ND 
and most of the available drugs fail to tackle ND pathogenesis. Numerous studies have been 
published about the role of the neurotrophin receptors in the pathogenesis of several 
neurodegenerative conditions (Simmons, D.A., et al. J. Neurosci. 2013, 33(48), 18712–27). There are 
two types of neurotrophin receptors: a non-enzymatic, trans-membrane protein of the tumour 
necrosis receptor (TNFR) family—p75, and the tyrosine kinase receptors (Trks) A, B and C. Trk 
receptors are activated, specifically, and with high affinity, by nerve growth factor (NGF) (TrkA), 
brainderived growth factor and neurotrophin 4/5 (BDNF and NT-4/5) (TrkB), and neurotrophin 3 
(NT3) (TrkC), whereas p75 is activated by all mentioned neurotrophins (Meldolesi, J., et al. Pharmacol. 
Res. 2017, 121, 129–137). The implication of the TrkB receptor in the pathogenesis of several 
neurodegenerative conditions (Alzheimer′s, Parkinson′s, and Huntington′s disease) point to the 
therapeutic potential of TrkB agonists (Nomura, T., et al. J. Neurosci. 2017, 37(47), 11298–11310; Zheng, 
H., et al. J. Metab. Brain Dis. 2018, 33, 1961). 
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Neurodegenerative diseases (ND), such as Alzheimer′s disease, Parkinson′s disease, multiple
sclerosis and motor neuron disease, are on the rise worldwide. Currently, there is no cure for any ND
and most of the available drugs fail to tackle ND pathogenesis. Numerous studies have been published
about the role of the neurotrophin receptors in the pathogenesis of several neurodegenerative conditions
(Simmons, D.A., et al. J. Neurosci. 2013, 33(48), 18712–27). There are two types of neurotrophin receptors:
a non-enzymatic, trans-membrane protein of the tumour necrosis receptor (TNFR) family—p75, and the
tyrosine kinase receptors (Trks) A, B and C. Trk receptors are activated, specifically, and with high
affinity, by nerve growth factor (NGF) (TrkA), brainderived growth factor and neurotrophin 4/5 (BDNF
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and NT-4/5) (TrkB), and neurotrophin 3 (NT3) (TrkC), whereas p75 is activated by all mentioned
neurotrophins (Meldolesi, J., et al. Pharmacol. Res. 2017, 121, 129–137). The implication of the
TrkB receptor in the pathogenesis of several neurodegenerative conditions (Alzheimer′s, Parkinson′s,
and Huntington′s disease) point to the therapeutic potential of TrkB agonists (Nomura, T., et al.
J. Neurosci. 2017, 37(47), 11298–11310; Zheng, H., et al. J. Metab. Brain Dis. 2018, 33, 1961).
After conducting in silico studies on the crystal structure of the TrkB receptor in order to determine
the most important interactions between TrkB and its natural ligand—neurotrophin-4/5 (NT-4/5)
(Figure 20a)—we performed in silico screening of the unique CERMN (Centre d’Etudes et de Recherche
sur le Médicament de Normandie) library of compounds. The screening was done on the basis of
the pharmacophore hypothesis (Figure 20b) developed from interactions of TrkB and its synthetic
ligand—LM22A-4 (Massa, S.M., et al. J. Clin. Invest. 2010, 120, 1774–1785). On the basis of the main
structural features of the LM22A-4, we designed a small dataset of the new potential TrkB agonists and
conducted the synthesis of the compounds with best in silico results.Pharmaceuticals 2019, 12, x FOR PEER REVIEW 37 of 47 
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(P27) 
Mohammed Aldholmi 1,2 and A. Ganesan 1 
1 School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, United 
Kingdom. 
2 Natural Products and Alternative Medicine, College of Clinical Pharmacy, Imam Abdulrahman Bin Faisal 
University, Dammam 31441, Saudi Arabia; e-mail: m.aldholmi@uea.ac.uk 
Aspergillus species are rich source of bioactive metabolites. However, most natural product 
biosynthetic pathways are silent under laboratory conditions. The epigenetic processes, including the 
covalent modifications of DNA and amino acids on histones, have been revealed to be extensively 
used by organisms to regulate the expression of genes involved in natural product biosynthesis 
(Felsenfeld, G., et al. Nature 2003, 421(6921), 448–453; Cichewicz, R. H. et al. Nat. Prod. Rep. 2010, 27(1), 
11–22). Therefore, it is possible to influence these processes during microbial fermentation by the 
addition of chemical epigenetic modulators (Cichewicz, R. H, et al. Nat. Prod. Rep. 2010, 27(1), 11–22; 
Williams, R.B., et al. Org. Biomol. Chem. 2008, 6(11), 1895–1897). 
Five Aspergillus strains were cultivated in the presence of Histone Deacetylase Activity (HDAC) 
inhibitors (e.g., vorinostat) or DNA methyltransferase (DNMT) inhibitors (e.g., 5-azacytidine). 
Morphological changes were monitored for 7 days before extraction with ethyl acetate or methanol. 
The extracts were analysed by HPLC and LC-MS, and the metabolic profiles were compared using 
chromatogram overlay and volcano plots. 
The overlayered chromatograms and volcano plots presented significant differences between 
the cultures treated with epigenetic modifiers and control cultures. Two induced bioactive 
metabolites were isolated from Aspergillus westerdijkiae and Aspergillus calidoustus, and their 
structures were elucidated using mass spectrometry and NMR. 
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7.27. Isolation and Structure Elucidation of Aspergillus Metabolites Induced with Epigenetic Modulators (P27)
Mohammed Aldholmi 1,2 and A. Ganesan 1
1 School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK
2 Natural Products and Alternative Medicine, College of Clinical Pharmacy, Imam Abdulrahman Bin
Faisal University, Dammam 31441, Saudi Arabia; m.aldholmi@uea.ac.uk
Aspergillus species are rich source of bioactive metabolites. However, most natural product
biosynthetic pathways are silent under laboratory conditions. The epigenetic processes, including the
covalent modifications of DNA and amino acids on histones, have been revealed to be extensively used
by organisms to regulate the expression of genes involved in natural product biosynthesis (Felsenfeld,
G., et al. Nature 2003, 421(6921), 448–453; Cichewicz, R. H. et al. Nat. Prod. Rep. 2010, 27(1), 11–22).
Therefore, it is possible to influence these processes during microbial fermentation by the addition of
chemical epigenetic odulators (Cichewicz, R. H, et al. Nat. Prod. Rep. 2010, 27(1), 11–22; Williams,
R.B., et al. Org. Biomol. Chem. 2008, 6(11), 1895–1897).
Five Aspergillus strains were cultivated in the presence of Histone Deacetylase Activity (HDAC)
inhibitors (e.g., vorinostat) or DNA methyltransferase (DNMT) inhibitors (e.g., 5-azacytidine).
Morphological changes were monitored for 7 days before extraction with ethyl acetate or methanol.
The extracts were analysed by HPLC and LC-MS, and the metabolic profiles were compared using
chromatogram overlay and volcano plots.
The overlayered chromatograms and volcano plots presented significant differences between the
cultures treated with epigenetic modifiers and control cultures. Two induced bioactive metabolites were
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isolated from Aspergillus westerdijkiae and Aspergillus calidoustus, and their structures were elucidated
using mass spectrometry and NMR.
I would like to thank Imam Abdulrahman Bin Faisal University for their financial support.
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1 Aix-Marseille Univ, CNRS, ICR UMR 7273, PCR, Faculté de Pharmacie, 13385 Marseille
2 Aix-Marseille Univ, IHU Méditerranée Infection, UMR VITROME, 13005 Marseille
3 Université Paul Sabatier, CNRS UPR 8241, LCC, 31077 Toulouse; nicolas.primas@univ-amu.fr
Malaria is still the leading cause of death among parasitic infections worldwide (WHO, World
Malaria report, 2018, http://www.who.int/malaria/publications/world-malaria-report-2018/report/en/).
The emergence and the expansion of Plasmodium strains resistant to the artemisinin-based combination
therapies (ACTs) are now threatening the efficacy of malaria treatment, notably in the Greater Mekong
sub-region. Therefore, new molecules displaying the original mode of action are urgently required.
Aiming at developing new antiplasmodials, our laboratory previously described the synthesis and
the biological activities of a library of 2-trichloromethylquinazoline derivatives, which highlighted
a hit molecule 1 (IC50 = 0.4 µM, CC50 = 16 µM) (Cominetti, M. D. D., et al. Org. Biomol. Chem.
2016, 14, 10161–10164; Verhaeghe, P., et al. Bioorg. Med. Chem. 2009, 17, 4313–4322) (Figure 21).
Moreover, a scaffold-hopping strategy showed that the replacement of the quinazoline moiety by a
quinoxaline one improved the cytotoxicity profile (Desroches. J., et al. Eur J. Med. Chem. 2017, 125,
68–86). Thus, we synthetized a new series of 2-trichloromethylquinoxaline analogues. The in vitro
biological evaluations against the multi-resistant K1 P. falciparum strain highlighted two new hit
molecules substituted by an electron-withdrawing group in para-position. Accordingly with these
results, we prepared new 2-trichloromethylquinoxaline analogues bearing other electron-withdrawing
groups such as -CF3, -SF5 or -OCF3.
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In parallel, to complete the global SAR study using the scaffold hopping approach, we replaced the
quinoxaline ring with a phthalazine one. The importance for the antiplasmodial activity of the phenyl
ring contained in the bicyclic quinazoline and quinoxaline scaffolds was also studied by structural
simplification, leading to the related pyrimidine and pyrazine analogues. The synthesis details of the
new an logues of it 1 in various series and the biologic l results will be described in the poster.
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The histamine H1 receptor (H1R) is a class A GPCR and is widely expressed throughout the
human body. H1R-dependent signalling is responsible for allergic reactions, plays an important
role in immunomodulation and, as recent studies have suggested, is involved in mediating cell
proliferation and thus cancer progression (Panula, P., et al. Pharmacol Rev. 2015, 67 (3), 601–655). High
affinity H1R fluorescent ligands with optimum physicochemical properties would serve as a valuable
tool to probe in further detail H1R cancer pharmacology and drug discovery (McGrath, J. C., et al.
The Adrenergic Receptors, Springer: 2006; pp 151–172; Vernall, A. J., et al. British J. Pharmacol.
2014, 171 (5), 1073–1084). Fluorescent ligands comprise a receptor binding element (either an
orthostere or allostere) linker connect to an appropriate fluorophore. Whilst modulating the overall
physicochemical properties of the fluorescent ligand, a peptide-based linker could engage in receptor
binding through its side chain functional groups, potentially improving binding affinity of the overall
conjugate and providing information on SAR along the receptor exit tunnel. The crystal structure of
H1R in complex with the antagonist doxepin was reported in 2011, providing detailed information of
the orthosteric binding site and revealing an additional binding site lined by the basic amino acids of
Lys179, Lys191 and His450, which could be targeted to improve ligand affinity (Shimamura, T., et al.
Nature 2011, 475 (7354), 65–70).
We envisaged optimising the peptide linker for a previously reported H1R fluorescent ligand
(Stoddart, L. A., et al. Scientific Reports 2018, 8 (1), 1572) with pKD of 8.1 by sequential screening
for amino acids along the peptide chain in order to identify those that could provide the greatest
improvement in binding affinity. By incorporating these amino acids into the linker, we synthesised
H1R fluorescent ligands with pKD′s ranging from 7.8 to 8.4. Molecular docking of these ligands into an
H1R crystal structure suggested the existence of small binding pockets along the receptor exit tunnel that
were exploited by the functionalised peptide linkers. Further experimentation with fluorescent ligands
of varying fluorophores suggested that the attachment of the boron-dipyrromethene BODIPY630/650
fluorophore was the main driving force in binding affinity in H1R fluorescent ligands. Despite not
being able to significantly improve binding affinities of H1R fluorescent ligands, optimisation of the
peptide linker provided information on SAR along the receptor exit tunnel.
7.30. First Design of MT5-MMP Inhibitors, a Challenging New Target for Alzheimer′s Disease (P30)
Pauline Zipfel 1, Julien Lalut 1, Camille Denis 1, Ronan Bureau 1, Peggy Suzanne 1, Audrey Davis 1,
Aurélie Malzert-Fréon 1, Kevin Baranger 2, Michel Khrestchatisky 2, Santiago Rivera 2,
Christophe Rochais 1 and Patrick Dallemagne 1
1 Centre d′Etudes et de Recherche sur le Médicament de Normandie (CERMN), Normandie Univ,
UNICAEN, 14000 Caen, France
2 Institute of Neuropathophysiology (INP), UMR7051, CNRS, Aix Marseille Université, France;
pauline.zipfel@unicaen.fr
In 2018, the number of people living with dementia in the world was estimated at 50 million,
and Alzheimer′s disease (AD) is the most common form of dementia. AD is a neurodegenerative and
incurable brain disorder; only treatments for symptoms are available at this time. Because of the heavy
economic and societal impacts, there is an urgent need to find new treatments that target the molecular
causes of neuronal cell death. Two abnormal structures in the brain called β-amyloid (Aβ)-containing
plaques and neurofibrillary tangles are considered as two of the main features of AD. In this context,
several studies support the hypothesis that alterations in the processing of amyloid precursor protein
(APP) contributes to AD pathogenesis, resulting in the accumulation of β-amyloid peptides (Aβ) and
other proteolytic products. Thus, current research focuses on the enzymes involved in APP cleavage
such as α-, β- and γ-secretases. However, recent studies have revealed the existence of another
physiological APP processing pathway, mediated by a novel AD-related enzyme, membrane-type
5-matrix metalloproteinase (MT5-MMP), which can process APP and promote Aβ accumulation,
as well as the inflammatory process in AD transgenic mice (Baranger, K., et al. Cell. Mol. Life Sci.
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2016, 73(1), 217–236); Baranger, K. et al. J. Neuroinflammation 2016, 13(1), 167–170); Baranger, K., et al.,
Front. Mol. Neurosci. 2017, 9, 1–17). Moreover, MT5-MMP can cleave APP upstream from the
β-secretase cleavage site (the so called η-cleavage site) (Ahmad, M. et al., J. Biochem. 2006, 139(3),
517–526) and release an N-terminally elongated Aβ fragment (Aη-α), which appears to be synaptotoxic
(Willem, M., et al. Nature 2015, 526(7573), 443–447). We aim to design and synthesize first selective
MT5-MMP inhibitors through an interdisciplinary approach including molecular modelling, medicinal
chemistry and biology. Starting from a cyclopentathiophene derivative identified by in silico screening,
we are currently investigating the pharmacomodulations on this hit compound to gain in affinity and
selectivity for MT5-MMP.
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Malaria is an infectious disease caused by the parasite of the genus Plasmodium with hu an
infection caused by species falciparum, malaria, knowlesi, vivax and ovale (De Koning-ward, T. F.,
et al. Nat. Publ. Gr. 2016, 14, 494–507). P. falciparum is associated with the most severe form of
malaria, responsible for ≈400,000 deaths/year, especially in Africa. A number of antimalarial drugs
are currently used to treat malaria. However, P. falciparum has developed resistance to all currently
used medicines, hence, there is a great need for the development of new drugs. Here, we report
novel quinolines as antimalarial leads. The quinolines were originally designed to be inhibitors of
NRH—quinone oxidoreductase 2 (NQO2), a potential therapeutic target in cancer chemotherapy
(Alnabulsi, S., et al. Bioorg. Med. Chem. Lett. 2018; 9, 1–6). P. falciparum contains a functionally
similar type II NADH/dehydrogenase known as Pf NDH2; therefore, these compounds were tested
against Plasmodium falciparum as antimalarial leads. The quinolines were identified as a potent in vitro
inhibitor of the multi-drug-resistant strain K1 of P. falciparum (with EC50 ranging from 0.5–20 µM).
The EC50 speed assays carried out to verify onset of antimalarial activity showed that the compounds
were fast-acting, as the EC50 values were achieved at 24 h. Cell cytotoxicity assays showed that the
compounds were very toxic towards HepG2 hepatic cancer cell lines seeded at 4000 cells/well, with low
selectivity indices (SI 0.6–2.7). The compounds were screened further against MDBK bovine kidney
cells, which showed improved selectivity indices (SI 1.6 > 10). To achieve further dose reduction and
to minimize toxicity, Calcusyn-based drug interactivity assays are ongoing. Further studies are in
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progress to characterize stage specificity, mechanism of action, cytotoxicity profiles and drug interaction
with existing antimalarial drugs.
7.32. Design, Synthesis and Biological Evaluation of New Fluorinated Indazole Derivates as Potential New
5-HT4R PET Radiotracers (P32)
Reynald Mangeant 1, Silvia Stiebing 1, Thomas Cailly 1,2, Audrey Davis 1, Frederic Fabis 1 and
Valerie Collot 1
1 Normandie univ, UNICAEN, CERMN, 14000 Caen, France
2 Department of Nuclear Medecine, CHU Côte de Nacre, 14000 Caen, France; reynald.mangeant@unicaen.fr
Since its discovery in 1988, the serotonin 4 receptor subtype (5-HT4R) has emerged as a promising
target for drug discovery and development, resulting from their implications in learning, cognition,
memory processes and many neuropsychiatric disorders such as Alzheimer′s disease, anxiety,
depression or anorexia nervosa (Bockaert, J., et al. Neuropharmacology 2008, 55 (6), 922–931). Thus,
discovery of active 5-HT4R agonists and antagonists remains a continuing interest in clinical research.
To this end, positron emission tomography (PET) (Marner, L., et al. Neuroimage 2010, 50 (3), 855–861;
Caillé, F., et al. Bioorg. Med. Chem. Lett. 2013, 23 (23), 6243–6247) coupled with effective radioligands
constitutes a valuable tool, both in clinical studies and drug discovery programmes. On the basis of
previous works in CERMN (Lam, B. V., et al. Chem. Eur. J. 2016, 22 (13), 4440–4446), we aimed to
develop new fluorinated indazole derivates as potential brain 5-HT4R PET tracers (Figure 22).
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Figure 22. Essential steps to obtain radiotracers. CL: cold ligands, PET: positron emission tomography.
This synthesis was carried out in three essential steps. A convergent synthesis pathway to obtain
cold ligands (CL) was established. A methodology allowing selective functionalization at position 3
leading to polyfunctional indazoles in a few steps was developed. New pharmacomodulations
studies were realized in order to increase receptor affinity, decrease lipophilicity and increase
metabolic resistance.
More than 20 compounds with nanomolar affinity were synthesized. One of them, MR35806,
is currently radiolabeled with fluorine 18 to obtain our first brain 5-HT4R PET tracer. This compound
will be tested in vivo on mouse brain.
The authors are grateful for the financial support by regional council of Normandy, FEDER and
Crunch Network.
7.33. Acetoxystachybotrydial Acetate, a Natural Compound Isolated from Stachybotrys Chartarum is a Potent
Inhibitor of Human Protein Casein Kinase 2 (CK2) (P33)
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1 Institut für Pharmazeutische und Medizinische Chemie, PharmaCampus, und 2Institut für
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Human protein kinase CK2 is an emerging target for drug design. Overexpression of CK2 is closely
related to many types of human cancer. It has been shown that elevated levels of CK2 protect tumour
cells from apoptosis (Faust M, Montenarh M. Cell Tissue Res 2000, 301, 329–340). Inhibition of CK2
activity can lead tumour cells into apoptosis, whereas viability of healthy cells is not affected (Ruzzene,
M., et al. Biochim. Biophys. Acta 2010, 1804, 499–504). Up until now, one ATP competitive inhibitor of
CK2, silmitasertib, is in phase-II clinical trials (Gowda, C., et al. Curr. Pharm. Des. 2017, 23, 95–107).
Here, we report on the screening of natural compounds isolated from Stachybotryschartarum (Gratz,
A., et al. Electrophoresis 2010, 31, 634–640). Twelve phenylspirodrimanes and three triphenylphenoles
were investigated on inhibitory activity towards CK2 using a capillary electrophoresis-based assay
(Jagels, A., et al. Mycotoxin Res. 2018, 34, 179–185). Triphenyl phenolestachybotrychromene C,
phenylspirodrimanes stachybotrydial acetate and acetoxystachybotrydial acetate with IC50 values of
0.3 µM, 0.7 µM and 1.9 µM, respectively, were identified as potent CK2 inhibitors (Figure 23). The effect
of these compounds on the proliferation of breast cancer cells MCF-7 was determined using an EdU
(5-ethynyl-2’-deoxyuridine) assay. For comparison, viability of breast cancer cells is shown below.
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Figure 23. 2D presentation of the interaction between the ATP binding site of CK2 with
acetoxystachybotrydial ace ate and stachybotrychromene C.
Cancer cells MCF-7 as well as lung cancer cells A427 and epidermal cancer cells A 431 were
tested using MTT ssay. In particular, acetoxystach botrydial acetate turned out to be the most
active compound. After treatment of MCF-7 cells with 1 µM for 24 h, cell proliferation was blocked
almost completely (99%), whereas cell viability was decreased only by 63%. Here, we describe
phenlyspirodrimanes as a new class of CK2 inhibitors, among them acetoxystachybotrydial acetate
whic has been proven to be the most potent representative of this series.
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The indolo [2, 3-b] quinoline system is present in many marine alkaloids that have demonstrated
interesting biological activity (for a review on biological activities, see: Lavrado, J., et al. Curr. Med.
Chem. 2010, 17, 2348–2370). Smiles rearrangement, an organic intramolecular nucleophilic aromatic
substitution reaction, provides a powerful access to the synthesis of a variety of heterocyclic compounds
(Figure 24). Taking advantage of the combination of Smiles rearrangement and radical chemistry,
preparation of new indolo [2, 3-b] quinoline derivatives and their biological evaluation will be presented
(Allart-Simon, I., et al. Molecules 2016, 21, 878–889; Pudlo, M., et al. Chem. Comm. 2012, 48, 2442–2444).
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Bile acids have conventionally been thought of as mere digestive surfactants that assist in the 
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can regulate bile acid met bolism. FXR, a member of nucle r receptor superfamily, plays a crucial
role in regulating bile acid homeosta is (Kullak-Ublick, G.A., et al. Physiology. 2008, 23(5), 286–295)
and an abundance of evidence suggests that FXR may be a useful target in the prevention of colon
carcinogenesis (Modica, S., t al. Cancer Res. 2008, 23, 9589–9595). It can be hypothesised that is bile
acids (the 3β-OH i omers of the normally occurring bile acids) can activate the FXR and regulate FXR
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We explored new synthetic approaches for producing isobile acids from natural bile acids, and a
panel of isobile acids and ormal bile acids were prepared in rd r to help in the ch ract rization of
their effect on cellular toxicity and on FXR activation.
We rea hed the conclusion that among the natural bile acids, CDCA was found to be the most
toxic, followed by LCA, CA and DCA. UDCA was least toxic, and this was as expected from many
studies on the relative toxicity of the bile acids, corresponding to the order of hydrophobicity of the
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bile acids. In general, the beta compounds (isobile acids) were less toxic than the alpha compounds.
Only in the case of LCA was there no difference in the toxicity of the epimeric pairs. Only isoCDCA
was found as a true FXR agonist on the basis of FXR FRET assay, whereas CDCA showed no significant
effect in FRET, which was surprising.Pharmaceuticals 2019, 12, x FOR PEER REVIEW 44 of 47 
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The occurrence of the 3-alkenyl-oxindole skeleton in various natural and synthetic products has 
generated interest of many groups on account of its useful biological properties and its versatility as 
a useful intermediate in the synthesis of many compounds (Bort, A., et al. Sci. Rep. 2018, 8, 4370). As 
part of our ongoing research on oxindole derivatives, we previously designed, synthesized and 
evaluated new series of bis-oxindoles as potent kinase inhibitors (Beauchard, A., et al. Bioorg. Med. 
Chem. 2006, 1, 6434–6443). In an effort to identify new pharmacological inhibitors of disease-relevant 
protein kinases with increased potency and selectivity, we launched a research program dealing with 
the synthesis of rare substituted 2-(2-oxoindolin-3-ylidene)acetonitrile derivatives bearing a sulphur 
atom directly attached on the external double bond. Few 3-(thiazol-5-ylidene)indoline-2-one 
derivatives I have been reported in the literature (Havrylyuk, D., et al. J. Med. Chem. 2012, 55, 8630–
8641; Erben, F., et al. RSC Adv. 2014, 4 (21), 10879–10893). To access the required 2-
oxoindolylacetonitrile derivatives III (Figure 27), we decided to explore a new route based on the 
application in synthesis of the reagent 4,5-dichloro-1,2,3-dithiazolium chloride (Appel salt) 1. The 
Figure 25. A measurement of toxicity of different bile acids. Caco-2 cells were treated with 100 µM bile
acid solution for 24 h, and cells were then treated with 10 µl of 2.5 mg/ml MTT reagent and incubated
for 2 h.
Pharmaceuticals 2019, 12, x FOR PEER REVIEW 44 of 47 
 
 
Figure 25. A measurement of toxicity of different bile acids. Caco-2 cells were treated with 100 µM 
bile acid solution for 24 h, and cells were then treated with 10 μl of 2.5 mg/ml MTT reagent and 
incubated for 2 h. 
 
Figure 26. Schematic representation the mechanism of BAS upon FXR activation. 
We reached the conclusion that among the natural bile acids, CDCA was found to be the most 
toxic, followed by LCA, CA and DCA. UDCA was least toxic, and this was as expected from many 
studies on the relative toxicity of the bile acids, corresponding to the order of hydrophobicity of the 
bile acids. In general, the beta compounds (isobile acids) were less toxic than the alpha compounds. 
Only in the case of LCA was there no difference in the toxicity of the epimeric pairs. Only isoCDCA 
was found as a true FXR agonist on the basis of FXR FRET assay, whereas CDCA showed no 
significant effect in FRET, which was surprising. 
We are most grateful to Dr. John O′Brien for NMR spectroscopy, Gary Hessman and Brian Talbot 
for MS spectroscopy and Tarek Moustafa for his collaboration in the FXR FRET assay. 
7.36. Synthesis and Biological Activities of New 2-Mercapto-(2-Oxoindolin-3-ylidene)acetonitrile 
Derivatives (P36) 
Boris Letribot, Régis Delatouche, Jean-René Chérouvrier, Lisianne Domon and Valérie Thiéry 
La Rochelle UniversityLIENSs UMR 7266, 17000-F La Rochelle, France; e-mail: valerie.thiery@univ-lr.fr 
The occurrence of the 3-alkenyl-oxindole skeleton in various natural and synthetic products has 
generated interest of many groups on account of its useful biological properties and its versatility as 
a useful intermediate in the synthesis of many compounds (Bort, A., et al. Sci. Rep. 2018, 8, 4370). As 
part of our ongoing research on oxindole derivatives, we previously designed, synthesized and 
evaluated new series of bis-oxindoles as potent kinase inhibitors (Beauchard, A., et al. Bioorg. Med. 
Chem. 2006, 1, 6434–6443). In an effort to identify new pharmacological inhibitors of disease-relevant 
protein kinases with increased potency and selectivity, we launched a research program dealing with 
the synthesis of rare substituted 2-(2-oxoindolin-3-ylidene)acetonitrile derivatives bearing a sulphur 
atom directly attached on the external double bond. Few 3-(thiazol-5-ylidene)indoline-2-one 
derivatives I have been reported in the literature (Havrylyuk, D., et al. J. Med. Chem. 2012, 55, 8630–
8641; Erben, F., et al. RSC Adv. 2014, 4 (21), 10879–10893). To access the required 2-
oxoindolylacetonitrile derivatives III (Figure 27), we decided to explore a new route based on the 
application in synthesis of the reagent 4,5-dichloro-1,2,3-dithiazolium chloride (Appel salt) 1. The 
Figure 26. Schematic representation the mechanism of BAS upon FXR activation.
We are most grateful to Dr. John O′Brien for NMR spectroscopy, Gary Hessman and Brian Talbot
for MS spectroscopy and Tarek Mous afa for his collaboration in the FXR FRET assay.
7.36. Synthesis and Biological Activities of New 2-Mercapto-(2-Oxoindolin-3-ylidene)acetonitrile
Derivatives (P36)
Boris Letribot, Régis Delatouche, Jea -René Chérouvrier, Lisianne Domon and Valérie Thiéry
La Rochell UniversityLIENSs UMR 7266, 17000-F La Rochelle, France; valerie.thiery@univ-lr.fr
The occurrence of the 3-alkenyl-oxindole skeleton in vari us natural and synthetic products has
generated intere t of many groups on account of its useful biological properties and its versatility as a
useful intermediate in the synthesis of many compounds (Bort, A., et al. Sci. Rep. 2018, 8, 4370). As part
of our ongoing research on oxindole derivatives, we previously desig ed, synthesized and evaluated
new series of bis-oxindoles as potent kinase inhibitors (Beauchard, A., et al. Bioorg. Med. Chem. 2006, 1,
6434–6443). In an effort to identify new pharmacol gical inhibitors of disease-relevant protein kinases
with increased potency and selectivity, we launched a research program dealing with the synthesis
of rare substituted 2-(2-oxoindolin-3-ylidene)acetonitrile derivatives bearing a sulphur atom directly
attached on the external double bond. Few 3-(thiazol-5-ylidene)indoline-2-one derivatives I have been
reported in the literature (Havrylyuk, D., et al. J. Med. Chem. 2012, 55, 8630–8641; Erben, F., et al.
RSC Adv. 2014, 4 (21), 10879–10893). To access the required 2-oxoindolylacetonitrile derivatives III
(Figure 27), we decided to explore a new route based on the application in synthesis of the reagent
4,5-dichloro-1,2,3-dithiazolium chloride (Appel salt) 1. The work described in this poster represents
further application of Appel salt in the conception of novel heterocyclic rings to access to original
bioactive compounds.
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Diversity selection methods in shape, scaffold, fingerprint and predicted property space 
combined with industry-standard substructure filtering were used to select over 2500 Key Organics 
compounds for experimental profiling. NMR and LC–MS analysis allowed the careful selection of 
highly-soluble fragments with desirable physicochemical and stability characteristics. Importantly, 
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Fragment libraries are commonly assembled by rule of three filtering followed by manual curation.
However, the robust experimental data that ensures the proper physicochemical attributes needed
for high-concentration screening is often lacking and replaced instead by in silico calculations of
uncertain predictive value. A fragment collection with experimentally-determined aqueous solubility
will address a major source of false positives and attrition in fragment screening libraries: aggregation,
stability and solubility. 1H NMR spectral data in aqueous buffer will further enable practitioners to
rapidly build fragment pools and initiate screening.
Diversity selection methods in shape, scaffold, fingerprint and predicted property space combined
with industry-standard substructure filtering were used to select over 2500 Key Organics compounds
for experimental profiling. NMR and LC–MS analysis allowed the careful selection of highly-soluble
fragments with desirable physicochemical and stability characteristics. Importantly, the curated
molecules were enriched in cyclic scaffolds commonly found in drug candidates and spanned chemical
space that minimally overlapped with existing commercial collections. This poster summarizes the
experimental and cheminformatic features of this next generation Key Organics ‘BIONET Premium
Fragment Library′. (Bradley, C., et al. J. Chem. Inf.Model. 2006, 46, 1060–1068; Baell, J. B., et al. J. Med.
Chem. 2010, 53, 2719–2740; Lagorce, D., et al. BMC Bioinformatics 2008, 9, 396; Kazius, J., et al. J. Med.
Chem. 2005, 48, 312–320; Bruns, R. F., et al. J. Med. Chem. 2012, 55, 9763–9772; Lisurek, M, et al. Mol.
Divers. 2010, 14(2), 401–408; Taylor, R. D., et al. J. Med. Chem. 2014, 57 (14), 5845–5859).
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7.38. Overcoming tumor necrosis factor (TNF)-Related Apoptosis Inducing Ligand (TRAIL) Resistance in
Cancer Stem Cells: Computer-Aided Discovery of c-FLIP Inhibitors
Kok Yung Lee 1, Andrea Brancale 1, Richard Clarkson 2 and Andrew Westwell 1
1 School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff CF10 3NB, UK
2 European Cancer Stem Cell Research Institute, Cardiff University, Cardiff CF24 4HQ, UK;
leek10@cardiff.ac.uk
The ability of cancer stem cells to self-renew indefinitely and differentiate into multiple tumour
cell types has made their elimination critical to completely eradicate tumours (Battle, E.; Clevers, H.
Nat Med. 2017, 23 (10), 1124–1134). TRAIL (TNF-related apoptosis inducing ligand) is a death ligand
that selectively induces apoptosis in cancer cells, but clinical trials utilising recombinant TRAIL or
TRAIL agonists have eventually failed due to the development of TRAIL resistance post-treatment (de
Miguel, D., et al. Cell Death Differ. 2016, 23 (5), 733–747; Herbst, R. S.; et al. J Clin Oncol. 2010, 28 (17),
2839–46)(Figure 28). c-FLIP (cellular FLICE-like inhibitory protein) inhibits TRAIL-mediated apoptosis
and its overexpression has since been identified as one of the mechanisms of TRAIL resistance present
in cancer stem cells (French, R.; et al. Mol Cancer. 2015, 14, 209). As a strategy to overcome TRAIL
resistance, this project aims to develop new small molecule inhibitors of c-FLIP that re-sensitises cancer
stem cells to TRAIL-mediated apoptosis.
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Twenty different compounds were identified through in silico screening as potential lead 
compounds targeting DEAD-box protein 1 (DED1) of c-FLIP. HeLa cells were treated with these 
compounds in combination with TRAIL to test for their ability to sensitise HeLa cells to TRAIL-
mediated apoptosis. Caspase-mediated apoptosis was confirmed through rescue with a pan-caspase 
inhibitor. Three of twenty compounds in combination with TRAIL successfully induced apoptosis in 
HeLa cells rescuable by caspase inhibitor. Further work is in progress to confirm c-FLIP inhibitor 
activity of these compounds through co-immunoprecipitation while analogues of the best performing 
lead compound are synthesised. 
7.41. University of Nottingham Managed Chemical Compound Collection (MCCC) (P41) 
Lubna Hashmi, Peter Fischer and Michael Stocks 
Centre for Biomolecular Sciences, University of Nottingham, Nottingham, Nottinghamshire NG7 2RD, United 
Kingdom; e-mail: michael.stocks@nottingham.ac.uk 
An Affordable and Automated Compound Management Facility 
.
enty ifferent co o n s ere i entifie thro gh in silico screening as otential lea
co o s targeti g -box rotei 1 ( 1) of c-F I . e a cells ere treate it t ese
co o n s in combination with TRAIL to test for their ability to sensitise HeLa cells to TRAIL-mediated
apoptosis. Caspase-mediated apoptosis was confirmed through rescue with a pan-caspase inhibitor.
Three of twenty compounds in combination with TRAIL successfully induced apoptosis in HeLa cells
rescuable by caspase inhibitor. Further work is in progress to confirm c-FLIP inhibitor activity of these
compounds through co-immunoprecipitation while analogues of the best performing lead compou d
are synthesised.
7.39. University of Nottingham Managed Chemical Compound Collection (MCCC) (P41)
Lubna Hashmi, Peter Fischer and Michael Stocks
Centre for Biomolecular Sciences, University of Nottingham, Nottingham, Nottinghamshire NG7 2RD,
UK; michael.stocks@nottingham.ac.uk
An Affordable and Automated Compound Management Facility
Pharmaceuticals 2019, 12, 179 47 of 47
• Compound library for high and medium throughput screening;
• >85K Structurally diverse drug-like molecules;
# Molecules obey Lipinski “rule of 5”;
# No reactive functional groups.
Purity Analysis and Structural Confirmation
• Samples stored at optimum condition as 10mM DMSO stock solutions;
• Dedicated LC–MS system to ensure purity of compounds.
Medicinal and Computation Chemistry Support
• Collaborative projects welcome.
For further information please contact:
Dr Michael Stocks; Head of Division of Medicinal Chemistry and Structural Biology;
michael.stocks@nottingham.ac.uk
8. Conclusions
The meeting attracted 114 delegates with successful growth of both the network membership
and the geographical range of attendee home countries, including France, Germany, Russia, Spain,
Portugal, Ireland, Italy and the United Kingdom. The programme comprised a discipline-leading
line-up of presenters from both academic and industrial sectors (including talks from 2 plenaries,
12 keynotes and 6 young researchers, and 41 posters), spanning a broad range of topics related to
medicinal chemistry. For the first time, the inclusion of a pre-conference workshop expanded attendee
knowledge and skills in the area of quantitative pharmacology. In addition, attendees of the conference
dinner enjoyed some words from Emeritus Prof. Malcolm Stevens FRS (UoN), who appropriately wore
a bowtie dyed with the original mauveine made by William Henry Perkin.
A number of prizes were awarded, with the best poster prize (sponsored by the Royal Society
of Chemistry) going to Mirjana Antonijevic (UNICAEN, France), the best young researcher oral
presentation to Scott Grossman (School of Pharmacy, University of Nottingham) and the MDPI
Pharmaceuticals travel award to Jorge Grilo (University of Lisbon).
The 28th Annual GP2A Medicinal Chemistry Conference will take place between 26 and 28 August
2020 at the University of La Rochelle, France.
The GP2A committee and the local organizing committee thank the Division of Biomolecular
Science and Medicinal Chemistry, School of Pharmacy (UoN), and all the sponsors and exhibitors for
supporting this annual event.
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